Document:

Exhibit 4.2

 

Form of Amended and Restated Underwriters’
Warrant Agreement

 

THE REGISTERED HOLDER OF
THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS
HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE
THIS PURCHASE WARRANT DURING THE TERM OF THIS WARRANT TO ANYONE OTHER THAN (I)  AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION
WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF ANY SUCH UNDERWRITER OR SELECTED DEALER.

 

THIS AMENDED AND RESTATED
PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO OCTOBER 27, 2017. VOID AFTER 5:00 P.M., EASTERN TIME, OCTOBER 27, 2021.

 

AMENDED AND RESTATED

COMMON STOCK PURCHASE WARRANT

 

For the Purchase of [_____] Shares of Common
Stock

of

AYTU BIOSCIENCE, INC

 

1.          Purchase
Warrant. THIS AMENDMENT CERTIFIES THAT, in consideration of funds previously duly paid to Aytu BioScience, Inc., a Delaware
Corporation (the “Company”) by or on behalf of [_____] (“Holder”), as registered owner of
this Amended and Restated Purchase Warrant (this “Purchase Warrant”), which amends and restates the Common Stock
Purchase Warrant issued to Holder on October 27, 2016, Holder is entitled, at any time or from time to time from October 27, 2017
(the “Commencement Date”), and at or before 5:00 p.m., Eastern time, October 27, 2021 (the ”Expiration Date”),
but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [_____] shares of common stock of the Company,
par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration
Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the
next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date,
the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is exercisable at $0.75
per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights
granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise,
shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the
adjusted exercise price, depending on the context.

 

2.          Exercise.

 

2.1          Exercise
Form. In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly executed and completed and
delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Shares being purchased
payable in cash by wire transfer of immediately available funds to an account designated by the Company or by certified check or
official bank check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time,
on the Expiration Date, this Purchase Warrant shall become and be void without further force or effect, and all rights represented
hereby shall cease and expire.

 

     

     

    

 

2.2         [Reserved]
 

 

2.3         Legend.
Each certificate for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities
have been registered under the Securities Act of 1933, as amended (the “Act”):

 

“The securities represented
by this certificate have not been registered under the Securities Act of 1933, as amended (the “Act”), or applicable
state law. Neither the securities nor any interest therein may be offered for sale, sold or otherwise transferred except pursuant
to an effective registration statement under the Securities Act, or pursuant to an exemption from registration under the Securities
Act and applicable state law which, in the opinion of counsel to the Company, is available.”

 

2.4.        Restrictive
Legend Events; Cashless Exercise Under Certain Circumstances.

 

2.4.1
     Restrictive Legend Events. If at any time after the Commencement Date there is no effective
registration statement registering, or no current prospectus available for, the resale of the Shares by a Holder (a
“Restrictive Legend Event”), then, to the extent that the Warrants cannot be exercised as a result of a
Restrictive Legend Event or a Restrictive Legend Event occurs after a Holder has exercised Warrants in accordance with the
terms of the Warrant but prior to the delivery of the Shares, the Company shall, at the election of the Holder, which shall
be given within five (5) days of receipt of such notice of the Restrictive Legend Event, either (A) rescind the previously
submitted Election to Purchase and the Company shall return all consideration paid by registered holder for such shares upon
such rescission or (B) treat the attempted exercise as a cashless exercise as described in paragraph (ii) below and refund
the cash portion of the exercise price to the Holder.

 

2.4.2      Cashless
Exercise Under Certain Circumstances. If a Restrictive Legend Event has occurred, the Warrant shall only be exercisable on
a cashless basis. Notwithstanding anything herein to the contrary, the Company shall not be required to make any cash payments
or net cash settlement to the Holder in lieu of delivery of the Shares. Upon a “cashless exercise”, the Holder shall
be entitled to receive the number of Shares equal to the quotient obtained by dividing (A-B) (X) by (A), where:

 

	 	(A)	= the VWAP on the Trading Day immediately preceding the Exercise Date;

 

	 	(B)	= the Exercise Price of the Warrant, as adjusted as set forth herein; and

 

	 	(X)	= the number of Shares that would be issuable upon exercise of the Warrant in accordance with the terms of the Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

 

If the Shares are issued in such a cashless
exercise, the Company acknowledges and agrees that, in accordance with Section 3(a)(9) of the Securities Act, the Shares shall
take on the registered characteristics of the Warrants being exercised and the Company agrees not to take any position contrary
thereto. A Holder shall promptly deliver a copy of the Election to Purchase to the Company to confirm the number of Shares issuable
in connection with the cashless exercise. The Company shall calculate and transmit to the Holder in a written notice, the number
of Shares issuable in connection with any cashless exercise.

 

    	 	2	 

     

    

 

		3.	Transfer.

 

3.1          General
Restrictions. The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder
will not at any time during the five year term of this Purchase Warrant: (a) sell, transfer, assign, pledge or hypothecate this
Purchase Warrant following the Effective Date to anyone other than: (i) an underwriter or a selected dealer participating in the
Offering, or (ii) a bona fide officer or partner of any such underwriter or selected dealer, in each case in accordance with FINRA
Conduct Rule 5110(g)(1), or (b) cause this Purchase Warrant or the securities issuable hereunder to be the subject of any
hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of this Purchase
Warrant or the securities hereunder, except as provided for in FINRA Rule 5110(g)(2). After the Effective Date, transfers to others
may be made subject to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment,
the Holder must deliver to the Company the assignment form attached hereto duly executed and completed, together with the Purchase
Warrant and payment of all transfer taxes, if any, payable in connection therewith. The Company shall within five (5) Business
Days transfer this Purchase Warrant on the books of the Company and shall execute and deliver a new Purchase Warrant or Purchase
Warrants of like tenor to the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number of Shares
purchasable hereunder or such portion of such number as shall be contemplated by any such assignment.

 

3.2           Restrictions
Imposed by the Securities Act. The securities evidenced by this Purchase Warrant shall not be transferred unless and until:
(i) the Company has received the opinion of counsel for the Holder that the securities may be transferred pursuant to an exemption
from registration under the Securities Act and applicable state securities laws, the availability of which is established to the
reasonable satisfaction of the Company (the Company hereby agreeing that the opinion of Sichenzia Ross Friedman Kesner LLP shall
be deemed satisfactory evidence of the availability of an exemption), or (ii) a registration statement or a post-effective amendment
to the Registration Statement relating to the offer and sale of such securities has been filed by the Company and declared effective
by the U.S. Securities and Exchange Commission (the ”Commission”) and compliance with applicable state
securities law has been established.

 

		4.	Registration Rights.

 

4.1          Demand
Registration.

 

4.1.1          Grant
of Right. The Company, upon written demand (a “Demand Notice”) of the Holder(s) of at least 51% of the Purchase
Warrants and/or the underlying Shares (“Majority Holders”), agrees to register, on one occasion, all or any portion
of the Shares underlying the Purchase Warrants (collectively, the “Registrable Securities”). On such occasion,
the Company will file a registration statement with the Commission covering the Registrable Securities within sixty (60) days after
receipt of a Demand Notice and use its reasonable best efforts to have the registration statement declared effective promptly thereafter,
subject to compliance with review by the Commission; provided, however, that the Company shall not be required to
comply with a Demand Notice if the Company has filed a registration statement with respect to which the Holder is entitled to piggyback
registration rights pursuant to Section 4.2 hereof and either: (i) the Holder has elected to participate in the offering covered
by such registration statement or (ii) if such registration statement relates to an underwritten primary offering of securities
of the Company, until the offering covered by such registration statement has been withdrawn or until thirty (30) days after such
offering is consummated. The demand for registration may be made at any time during a period of four (4) years beginning on the
Commencement Date. The Company covenants and agrees to give written notice of its receipt of any Demand Notice by any Holder(s)
to all other registered Holders of the Purchase Warrants and/or the Registrable Securities within ten (10) days after the date
of the receipt of any such Demand Notice.

 

    	 	3	 

     

    

 

4.1.2           Terms.
The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 4.1.1,
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. The Company agrees to use its reasonable best efforts
to cause the filing required herein to become effective promptly and to qualify or register the Registrable Securities in such
States as are reasonably requested by the Holder(s); provided, however, that in no event shall the Company be required
to register the Registrable Securities in a State in which such registration would cause: (i) the Company to be obligated to register
or license to do business in such State or submit to general service of process in such State, or (ii) the principal shareholders
of the Company to be obligated to escrow their shares of capital stock of the Company. The Company shall cause any registration
statement filed pursuant to the demand right granted under Section 4.1.1 to remain effective for a period of at least twelve (12)
consecutive months after the date that the Holders of the Registrable Securities covered by such registration statement are first
given the opportunity to sell all of such securities. The Holders shall only use the prospectuses provided by the Company to sell
the shares covered by such registration statement, and will immediately cease to use any prospectus furnished by the Company if
the Company advises the Holder that such prospectus may no longer be used due to a material misstatement or omission. Notwithstanding
the provisions of this Section 4.1.2, the Holder shall be entitled to a demand registration under this Section 4.1.2 on only one
(1) occasion and such demand registration right shall terminate on the fifth anniversary of the effectiveness of the registration
statement in accordance with FINRA Rule 5110(f)(2)(G)(iv).

 

	 	4.2	“Piggy-Back” Registration.

 

4.2.1          Grant
of Right. In addition to the demand right of registration described in Section 4.1 hereof, the Holder shall have the right,
for a period of no more than two (2) years from the date of effectiveness of the registration statement in accordance with FINRA
Rule 5110(f)(2)(G)(v), to include the Registrable Securities as part of any other registration of securities filed by the Company
(other than in connection with a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form
S-8 or any equivalent form); provided, however, that if, solely in connection with any primary underwritten public
offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation
on the number of shares of Common Stock which may be included in the Registration Statement because, in such underwriter(s)’
judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall
be obligated to include in such Registration Statement only such limited portion of the Registrable Securities with respect to
which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable Securities
shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities
sought to be included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities
unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities
in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.

 

4.2.2           Terms.
The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 4.2.1 hereof,
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company
shall furnish the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice prior to
the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration
statement filed by the Company during the two (2) year period following the Commencement Date until such time as all of the Registrable
Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise the “piggy-back”
rights provided for herein by giving written notice within ten (10) days of the receipt of the Company’s notice of its intention
to file a registration statement. Except as otherwise provided in this Purchase Warrant, there shall be no limit on the number
of times the Holder may request registration under this Section 4.2.2; provided, however, that such registration
rights shall terminate on the [sixth] anniversary of the Commencement Date.

 

    	 	4	 

     

    

 

	 	4.3	General Terms.

 

4.3.1          Indemnification.
The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder
and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20 (a) of
the Securities Exchange Act of 1934, as amended (“Exchange Act”), against all loss, claim, damage, expense or
liability (including all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or
defending against any claim whatsoever) to which any of them may become subject under the Securities Act, the Exchange Act or otherwise,
arising from such registration statement but only to the same extent and with the same effect as the provisions pursuant to which
the Company has agreed to indemnify the Underwriters contained in Section 5.1 of the Underwriting Agreement between the Underwriters
and the Company, dated as of October 27, 2016. The Holder(s) of the Registrable Securities to be sold pursuant to such registration
statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss, claim,
damage, expense or liability (including all reasonable attorneys’ fees and other expenses reasonably incurred in investigating,
preparing or defending against any claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act
or otherwise, arising from information furnished by or on behalf of such Holders, or their successors or assigns, in writing, for
specific inclusion in such registration statement to the same extent and with the same effect as the provisions contained in Section
5.2 of the Underwriting Agreement pursuant to which the Underwriters have agreed to indemnify the Company.

 

4.3.2           Exercise
of Purchase Warrants. Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s) to exercise
their Purchase Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.

 

4.3.3           Documents
Delivered to Holders. The Company shall furnish to each Holder participating in any of the foregoing offerings and to each
underwriter of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of
counsel to the Company, dated the effective date of such registration statement (and, if such registration includes an underwritten
public offering, an opinion dated the date of the closing under any underwriting agreement related thereto), and (ii) a “cold
comfort” letter dated the effective date of such registration statement (and, if such registration includes an underwritten
public offering, a letter dated the date of the closing under the underwriting agreement) signed by the independent registered
public accounting firm which has issued a report on the Company’s financial statements included in such registration statement,
in each case covering substantially the same matters with respect to such registration statement (and the prospectus included therein)
and, in the case of such accountants’ letter, with respect to events subsequent to the date of such financial statements,
as are customarily covered in opinions of issuer’s counsel and in accountants’ letters delivered to underwriters in
underwritten public offerings of securities. The Company shall also deliver promptly to each Holder participating in the offering
requesting the correspondence and memoranda described below and to the managing underwriter, if any, copies of all correspondence
between the Commission and the Company, its counsel or auditors and all memoranda relating to discussions with the Commission or
its staff with respect to the registration statement and permit each Holder and underwriter to do such investigation, upon reasonable
advance notice, with respect to information contained in or omitted from the registration statement as it deems reasonably necessary
to comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books, records and properties
and opportunities to discuss the business of the Company with its officers and independent auditors, all to such reasonable extent
and at such reasonable times as any such Holder shall reasonably request.

 

    	 	5	 

     

    

 

4.3.4           Underwriting
Agreement. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected by any
Holders whose Registrable Securities are being registered pursuant to this Section 4, which managing underwriter shall be reasonably
satisfactory to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each Holder
and such managing underwriters, and shall contain such representations, warranties and covenants by the Company and such other
terms as are customarily contained in agreements of that type used by the managing underwriter. The Holders shall be parties to
any underwriting agreement relating to an underwritten sale of their Registrable Securities and may, at their option, require that
any or all the representations, warranties and covenants of the Company to or for the benefit of such underwriters shall also be
made to and for the benefit of such Holders. Such Holders shall not be required to make any representations or warranties to or
agreements with the Company or the underwriters except as they may relate to such Holders, their Shares and their intended methods
of distribution.

 

4.3.5           Documents
to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company
a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.

 

4.3.6           Damages.
Should the registration or the effectiveness thereof required by Sections 4.1 and 4.2 hereof be delayed by the Company or the Company
otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to
the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened
breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without the
necessity of posting bond or other security.

 

		5.	New Purchase Warrants to be Issued.

 

5.1         Partial
Exercise or Transfer. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned in
whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation,
together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax
if exercised pursuant to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase
Warrant of like tenor to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number
of Shares purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned.

 

5.2          Lost
Certificate. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this
Purchase Warrant and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver
a new Purchase Warrant of like tenor and date. Any such new Purchase Warrant executed and delivered as a result of such loss, theft,
mutilation or destruction shall constitute a substitute contractual obligation on the part of the Company.

 

		6.	Adjustments.

 

6.1          Adjustments
to Exercise Price and Number of Securities. The Exercise Price and the number of Shares underlying the Purchase Warrant shall
be subject to adjustment from time to time as hereinafter set forth:

 

    	 	6	 

     

    

 

6.1.1          Share
Dividends; Split Ups. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding
Shares is increased by a stock dividend payable in Shares or by a split up of Shares or other similar event, then, on the effective
day thereof, the number of Shares purchasable hereunder shall be increased in proportion to such increase in outstanding Shares,
and the Exercise Price shall be proportionately decreased.

 

6.1.2           Aggregation
of Shares. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding Shares
is decreased by a reverse stock split, consolidation, combination or reclassification of Shares or other similar event, then, on
the effective date thereof, the number of Shares purchasable hereunder shall be decreased in proportion to such decrease in outstanding
Shares, and the Exercise Price shall be proportionately increased.

 

6.1.3           Replacement
of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding Shares other than
a change covered by Section 6.1.1 or 6.1.2 hereof or that solely affects the par value of such Shares, or in the case of any share
reconstruction or amalgamation or consolidation of the Company with or into another corporation (other than a consolidation or
share reconstruction or amalgamation in which the Company is the continuing corporation and that does not result in any reclassification
or reorganization of the outstanding Shares), or in the case of any sale or conveyance to another corporation or entity of the
property of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved, the Holder
of this Purchase Warrant shall have the right thereafter (until the expiration of the right of exercise of this Purchase Warrant)
to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder immediately prior to such event, the
kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization,
share reconstruction or amalgamation, or consolidation, or upon a dissolution following any such sale or transfer, by a Holder
of the number of Shares of the Company obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if
any reclassification also results in a change in Shares covered by Section 6.1.1 or 6.1.2, then such adjustment shall be made pursuant
to Sections 6.1.1, 6.1.2 and this Section 6.1.3. The provisions of this Section 6.1.3 shall similarly apply to successive reclassifications,
reorganizations, share reconstructions or amalgamations, or consolidations, sales or other transfers.

 

6.1.4           Changes
in Form of Purchase Warrant. This form of Purchase Warrant need not be changed because of any change pursuant to this Section
6.1, and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as are stated
in the Purchase Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase
Warrants reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after the
Commencement Date or the computation thereof.

 

6.2           Substitute
Purchase Warrant. In case of any consolidation of the Company with, or share reconstruction or amalgamation of the Company
with or into, another corporation (other than a consolidation or share reconstruction or amalgamation which does not result in
any reclassification or change of the outstanding Shares), the corporation formed by such consolidation or share reconstruction
or amalgamation shall execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder of each Purchase
Warrant then outstanding or to be outstanding shall have the right thereafter (until the stated expiration of such Purchase Warrant)
to receive, upon exercise of such Purchase Warrant, the kind and amount of shares of stock and other securities and property receivable
upon such consolidation or share reconstruction or amalgamation, by a holder of the number of Shares of the Company for which such
Purchase Warrant might have been exercised immediately prior to such consolidation, share reconstruction or amalgamation, sale
or transfer. Such supplemental Purchase Warrant shall provide for adjustments which shall be identical to the adjustments provided
for in this Section 6. The above provision of this Section shall similarly apply to successive consolidations or share reconstructions
or amalgamations.

 

    	 	7	 

     

    

 

6.3           Elimination
of Fractional Interests. The Company shall not be required to issue certificates representing fractions of Shares upon the
exercise of the Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being
the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down, as the case may
be, to the nearest whole number of Shares or other securities, properties or rights.

 

7.           Reservation
and Listing. The Company shall at all times reserve and keep available out of its authorized Shares, solely for the purpose
of issuance upon exercise of the Purchase Warrants, such number of Shares or other securities, properties or rights as shall be
issuable upon the exercise thereof. The Company covenants and agrees that, upon exercise of the Purchase Warrants and payment of
the Exercise Price therefor, in accordance with the terms hereby, all Shares and other securities issuable upon such exercise shall
be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder. The Company
further covenants and agrees that upon exercise of the Purchase Warrants and payment of the exercise price therefor, all Shares
and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject
to preemptive rights of any shareholder. As long as the Purchase Warrants shall be outstanding, the Company shall use its commercially
reasonable efforts to cause all Shares issuable upon exercise of the Purchase Warrants to be listed (subject to official notice
of issuance) on all national securities exchanges (or, if applicable, on the OTC Bulletin Board or any successor trading market)
on which the Shares issued to the public in the Offering may then be listed and/or quoted.

 

		8.	Certain Notice Requirements.

 

8.1          Holder’s
Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holders the right to vote or consent or to
receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder
of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the events
described in Section 8.2 shall occur, then, in one or more of said events, the Company shall give written notice of such event
at least fifteen days prior to the date fixed as a record date or the date of closing the transfer books for the determination
of the shareholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled
to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of
the closing of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to each Holder
a copy of each notice given to the other shareholders of the Company at the same time and in the same manner that such notice is
given to the shareholders.

 

8.2           Events
Requiring Notice. The Company shall be required to give the notice described in this Section 8 upon one or more of the following
events: (i) if the Company shall take a record of the holders of its Shares for the purpose of entitling them to receive a dividend
or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings,
as indicated by the accounting treatment of such dividend or distribution on the books of the Company, (ii) the Company shall offer
to all the holders of its Shares any additional shares of capital stock of the Company or securities convertible into or exchangeable
for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor, or (iii) a dissolution, liquidation
or winding up of the Company (other than in connection with a consolidation or share reconstruction or amalgamation) or a sale
of all or substantially all of its property, assets and business shall be proposed.

 

    	 	8	 

     

    

 

8.3           Notice
of Change in Exercise Price. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant to
Section 6 hereof, send notice to the Holders of such event and change (“Price Notice”). The Price Notice shall
describe the event causing the change and the method of calculating same and shall be certified as being true and accurate by the
Company’s Chief Financial Officer.

 

8.4           Transmittal
of Notices. All notices, requests, consents and other communications under this Purchase Warrant shall be in writing and shall
be deemed to have been duly made when hand delivered, or mailed by express mail or private courier service: (i) if to the registered
Holder of the Purchase Warrant, to the address of such Holder as shown on the books of the Company, or (ii) if to the Company,
to following address or to such other address as the Company may designate by notice to the Holders:

 

If to the Holder:

 

Attn:

Fax No.:

 

with a copy (which shall not constitute notice) to:

Sichenzia Ross Friedman Kesner LLP

61 Broadway

New York, New York 10006

Attn: Gregory Sichenzia, Esq.

Fax No.: (212) 930-9725

 

If to the Company:

 

Aytu Bioscience, Inc.

373 Inverness Parkway, Suite 206

Englewood, Colorado 80112

Attention: Joshua R. Disbrow, Chief Executive
Officer

Fax No:

 

with a copy (which shall not constitute notice) to:

 

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

Attention: Alexander M. Donaldson, Esq.

Fax No: (919) 7841-4865

  

		9.	Miscellaneous.

 

9.1          Amendments.
The Company and Joseph Gunnar, as Representative of the Underwriters (the “Representative”), may from time to time
supplement or amend this Purchase Warrant without the approval of any of the Holders in order to cure any ambiguity, to correct
or supplement any provision contained herein that may be defective or inconsistent with any other provisions herein, or to make
any other provisions in regard to matters or questions arising hereunder that the Company and the Representative may deem necessary
or desirable and that the Company and the Representative deem shall not adversely affect the interest of the Holders. All other
modifications or amendments shall require the written consent of and be signed by the party against whom enforcement of the modification
or amendment is sought.

 

    	 	9	 

     

    

 

9.2           Headings.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the
meaning or interpretation of any of the terms or provisions of this Purchase Warrant.

 

9.3.           Entire
Agreement. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection
with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and
supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.

 

9.4           Binding
Effect. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and
their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed
to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions
herein contained.

 

9.5           Governing
Law; Submission to Jurisdiction; Trial by Jury. This Purchase Warrant shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of laws principles thereof. Each of the Company and the
Holder hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant
shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the
Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. Each of the
Company and the holder hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient
forum. Any process or summons to be served upon the Company or the Holder may be served by transmitting a copy thereof by registered
or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8 hereof. Such
mailing shall be deemed personal service and shall be legal and binding upon the Company and the Holder in any action, proceeding
or claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from
the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred
in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf
of its stockholders and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law,
any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby.

 

9.6           Waiver,
etc. The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not
be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or
any provision hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase
Warrant. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be
effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver
is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any
other or subsequent breach, non-compliance or non-fulfillment.

 

    	 	10	 

     

    

 

9.7           Execution
in Counterparts. This Purchase Warrant may be executed in one or more counterparts, and by the different parties hereto in
separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and
the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and
delivered to each of the other parties hereto. Such counterparts may be delivered by facsimile transmission or other electronic
transmission.

 

9.8           Exchange
Agreement. As a condition of the Holder’s receipt and acceptance of this Purchase Warrant, Holder agrees that, at any
time prior to the complete exercise of this Purchase Warrant by Holder, if the Company and the Representative enter into an agreement
(“Exchange Agreement”) pursuant to which they agree that all outstanding Purchase Warrants will be exchanged
for securities or cash or a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.

 

[Signature Page Follows]

 

    	 	11	 

     

    

 

IN WITNESS WHEREOF, the Company has caused this
Amended and Restated Purchase Warrant to be signed by its duly authorized officer as of the ____ day of ______________, 2017.

 

	AYTU BIOSCIENCE, INC. 	 
	 	 	 
	By: 	 	 
	 	Name: 	 
	 	Title: 	 

 

     

     

    

 

[Form to be used to exercise Amended and
Restated Purchase Warrant]

 

Date: __________, 20___

 

The undersigned hereby
elects irrevocably to exercise the Amended and Restated Purchase Warrant (this “Purchase Warrant”) for ______
shares of common stock, par value $0.0001 per share (the “Shares”), of Aytu BioScience, Inc., a Delaware corporation
(the “Company”), and hereby makes payment of $____ (at the rate of $____ per Share) in payment of the Exercise
Price pursuant thereto. Please issue the Shares as to which this Purchase Warrant is exercised in accordance with the instructions
given below and, if applicable, a new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not
been exercised.

 

or

 

The undersigned hereby
elects irrevocably to convert its right to purchase ___ Shares of the Company under the Purchase Warrant for ______ Shares, as
determined in accordance with the following formula:

 

	 	 	 	Y(A-B)	 
	 	X	=	A	 

 

	Where,	 	 	 
	 	X	=	The number of Shares to be issued to Holder;
	 	Y	=	The number of Shares for which the Purchase Warrant is being exercised;
	 	A	=	The fair market value of one Share which is equal to $_____; and
	 	B	=	The Exercise Price which is equal to $______ per share

 

The undersigned agrees
and acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement with respect
to the calculation shall be resolved by the Company in its sole discretion.

 

Please issue the Shares
as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase
Warrant representing the number of Shares for which this Purchase Warrant has not been converted.

 

	Signature	 	 
	 	 	 
	Signature Guaranteed	 	 

 

INSTRUCTIONS FOR
REGISTRATION OF SECURITIES

 

	Name:	 	 
	 	(Print in Block Letters)	 
	 	 
	Address:	 	 
	 	 	 
	 	 	 

 

     

     

    

 

NOTICE: The signature to
this form must correspond with the name as written upon the face of the Purchase Warrant without alteration or enlargement or any
change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership
on a registered national securities exchange.

 

     

     

    

 

[Form to be used to assign Amended and Restated
Purchase Warrant]

 

ASSIGNMENT

 

(To be executed by the registered Holder to
effect a transfer of the within Purchase Warrant):

 

FOR VALUE RECEIVED, __________________ does
hereby sell, assign and transfer unto the right to purchase shares of common stock, par value $0.0001 per share, of Aytu BioScience,
Inc., a Delaware corporation (the “Company”), evidenced by the Amended and Restated Purchase Warrant (this “Purchase
Warrant”) and does hereby authorize the Company to transfer such right on the books of the Company.

 

Dated: __________, 20__

 

	Signature	 	 
	 	 	 
	Signature Guaranteed	 	 

 

NOTICE: The signature to this form must correspond
with the name as written upon the face of the within Purchase Warrant without alteration or enlargement or any change whatsoever,
and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered
national securities exchange.Corindus Vascular Robotics, Inc. 8-K

 

Exhibit 10.1

 

 

SECURITIES PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “Agreement”) is dated as of February 28, 2017, by
and between Corindus Vascular Robotics, Inc., a Delaware corporation (the “Company”), and each
Purchaser identified on Exhibit A hereto (each, including its successors and assigns, a
“Purchaser” and collectively, the “Purchasers”).

 

Recitals

 

A.       This
Agreement is being executed by the Company and each Purchaser in connection with the private placement offering (the “Offering”)
of the common stock, par value $0.0001 per share, of the Company (the “Common Stock”), at the Purchase
Price per share.

 

B.       The
Company and each Purchaser is executing and delivering this Agreement in reliance upon an exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or
Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission
(the “Commission”) under the Securities Act.

 

C.       Each
Purchaser, severally and not jointly, wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated
in this Agreement, that aggregate number of shares of Common Stock, determined as set forth in Section 2.1(a) below (which aggregate
amount for all Purchasers together shall be collectively referred to herein as the “Shares”); the Shares
may also be referred to herein as the “Securities”.

 

D.       Prior
to the Closing, the parties hereto will execute and deliver a Registration Rights Agreement, substantially in the form attached
hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which, among other things,
the Company will agree to provide, with respect to the Shares, certain registration rights under the Securities Act and the rules
and regulations promulgated thereunder and applicable state securities laws.

 

Now,
Therefore, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers hereby agree as follows:

 

Article
1

DEFINITIONS

 

1.1       Definitions.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms shall have
the meanings indicated in this Section 1.1:

 

“Action”
means any action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation
pending or, to the Company’s Knowledge, threatened in writing (or otherwise) against the Company or any of its Subsidiaries
or properties or any officer, director or employee of the Company as of the date hereof acting in his or her capacity as an officer,
director or employee of the Company before or by any federal, state, county, local or foreign court, arbitrator, governmental or
administrative agency, regulatory authority, stock market, stock exchange or trading facility.

 

     

     

    

 

“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, Controls,
is controlled by or is under common control with such Person; provided, however, that, for purposes of Section 3.2(h), Section
4.7 and Section 4.8 of this Agreement, no Purchaser shall be deemed to Control, be controlled by, or be under common control with,
or be an Affiliate of, the Company or any of its subsidiaries, or vice versa.

 

“Agreement”
has the meaning set forth in the preamble.

 

“Applicable Laws”
has the meaning set forth in Section 3.1(o).

 

“Board”
means the Board of Directors of the Company.

 

“Boston Courts”
means the state and federal courts sitting in Boston, Massachusetts.

 

“Business Day”
means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in the Commonwealth of Massachusetts are authorized or required by law or other governmental action to close.

 

“Closing”
means the closing of the purchase by the Purchasers and sale by the Company of the Shares to such Purchasers pursuant to this Agreement.

 

“Closing Date”
means the date on which a Closing occurs as provided in Section 2.1(b) hereof.

 

“Commission”
has the meaning set forth in the Recitals.

 

“Common Stock”
has the meaning set forth in the Recitals.

 

“Company”
has the meaning set forth in the preamble.

 

“Company Counsel”
means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., with offices located at One Financial Center, Boston, Massachusetts
02111.

 

“Company Deliverables”
has the meaning set forth in Section 2.2(a).

 

“Company Product”
has the meaning set forth in Section 3.1(p).

 

“Company’s
Knowledge” means with respect to any statement made to the knowledge of the Company, that the statement is based
upon the actual knowledge of the officers of the Company who, as of the date hereof, have responsibility for the matter or matters
that are the subject of the statement, and the knowledge that each such person would have reasonably obtained in the performance
of each such person’s duties as an officer of the Company.

 

“Compliance Certificate”
has the meaning set forth in Section 2.2(a)(vi).

 

“Control”
(including the terms “controlling”, “controlled” by or “under common
control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management
and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

 

“Disclosure Materials”
has the meaning set forth in Section 3.1(h).

 

“Disclosure Schedule”
has the meaning set forth in Section 3.1.

 

    1 

     

    

 

“Disqualification
Events” has the meaning set forth in Section 3.1(ll).

 

“Covered Persons”
has the meaning set forth in Section 3.1(ll).

 

“Solicitor”
has the meaning set forth in Section 3.1(ll).

 

“DTC”
has the meaning set forth in Section 4.1(c).

 

“Environmental
Laws” has the meaning set forth in Section 3.1(l).

 

“Evaluation Date”
has the meaning set forth in Section 3.1(u).

 

“ERISA”
has the meaning set forth in Section 3.1(ii).

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

“FDA”
has the meaning set forth in Section 3.1(o).

 

“GAAP”
means U.S. generally accepted accounting principles.

 

“Indemnified Person”
has the meaning set forth in Section 4.8(b).

 

“Intellectual Property”
has the meaning set forth in Section 3.1(r).

 

“Irrevocable Transfer
Agent Instructions” means, with respect to the Company, the Irrevocable Transfer Agent Instructions, in the form
of Exhibit E, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent.

 

“Lien”
means any material lien, charge, claim, encumbrance, security interest, right of first refusal, preemptive right or other restrictions
of any kind.

 

“Material Adverse
Effect” means a material adverse effect on the (i) validity or enforceability of or the Company’s ability to
perform in any material respect its obligations under this Agreement or (ii) earnings, results of operations, assets, properties,
business or condition (financial or otherwise) of the Company and its subsidiaries, taken as a whole, except that any of the following,
either alone or in combination, shall not be deemed a Material Adverse Effect: (i) effects caused by changes or circumstances affecting
general market conditions in the U.S. or applicable foreign economy or effects generally applicable to the industry in which the
Company operates, (ii) effects resulting from or relating to the announcement or disclosure of the sale of the Securities or other
transactions contemplated by this Agreement, (iii) effects caused by any event, occurrence or condition resulting from or relating
to the taking of any action in accordance with this Agreement, (iv) changes
in the trading price or trading volume of the Company’s Common Stock (but not the underlying causes thereof), (v)
the filing of any stockholder or derivative litigation arising from or relating
to the execution of this Agreement or the consummation of the transactions contemplated hereby, or (vi) effects caused by earthquakes,
hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities,
acts of war, sabotage or terrorism or military actions existing as of the date hereof, except, with respect to clauses (i) and
(vi), to the extent that the effects of such changes or events are disproportionately adverse to the earnings, results of
operations, assets, properties, business or condition (financial or otherwise) of the Company and its subsidiaries, taken as a
whole.

 

    2 

     

    

 

“Material Contract”
means any contract of the Company that has been filed as an exhibit to the SEC Reports pursuant to Item 601(b)(4) or Item 601(b)(10)
of Regulation S-K.

 

“Material Permits”
has the meaning set forth in Section 3.1(p).

 

“Money Laundering
Laws” has the meaning set forth in Section 3.1(ff).

 

“Outside Date”
means the twentieth (20th) Business Day following the date of this Agreement.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Principal Trading
Market” means the Trading Market on which the Common Stock is primarily listed on or quoted for trading, which, as
of the date of this Agreement and the Closing Date, shall be the NYSE-MKT.

 

“Proceeding”
means an Action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding,
such as a deposition).

 

“Purchase
Price” means $0.6616.

 

“Purchaser”
or “Purchasers” has the meaning set forth in the preamble.

 

“Purchaser Deliverables”
has the meaning set forth in Section 2.2(b).

 

“Purchaser Party”
has the meaning set forth in Section 4.8(a).

 

“Registration Rights
Agreement” has the meaning set forth in the recitals.

 

“Registration Statement”
means a registration statement meeting the requirements set forth in the Registration Rights Agreement and covering the resale
by the Purchasers of the Registrable Securities (as defined in the Registration Rights Agreement).

 

“Regulation D”
has the meaning set forth in the Recitals.

 

“Required Approvals”
has the meaning set forth in Section 3.1(e).

 

“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or
any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Sanctions”
has the meaning set forth in Section 3.1(gg).

 

“Sanctioned Persons”
has the meaning set forth in Section 3.1(gg).

 

“Sanctioned Country”
and “Sanctioned Countries” have the meanings set forth in Section 3.1(gg).

 

    3 

     

    

 

“SEC Reports”
has the meaning set forth in Section 3.1(h).

 

“Secretary’s
Certificate” has the meaning set forth in Section 2.2(a)(vi).

 

“Securities Act”
has the meaning set forth in the recitals.

 

“Shares”
has the meaning set forth in the Recitals.

 

“Short
Sales” include, without limitation, (i) (A) all “short sales” as defined in Rule 200 promulgated under
Regulation SHO under the Exchange Act, whether or not against the box, and (B) all types of direct and indirect stock pledges,
forward sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h)
under the Exchange Act) and similar arrangements (including on a total return basis) that have an economically similar result
to a “short sale” as defined in Rule 200, and (ii) sales and other transactions through
non-U.S. broker dealers or foreign regulated brokers that have an economically similar result to a “short sale”
as defined in Rule 200.

 

“Stock Certificates”
has the meaning set forth in Section 2.2(a)(iv).

 

“Subscription Amount”
has the meaning set forth in Section 2.1(a).

 

“Subsidiary”
means any entity in which the Company, directly or indirectly, owns capital stock or holds an equity or similar interest.

 

“Trading Affiliate”
has the meaning set forth in Section 3.2(h).

 

“Trading Day”
means (i) a day on which the Common Stock is listed or quoted and traded on its Principal Trading Market (unless the Principal
Trading Market is the OTC Bulletin Board or the OTC Pink tier of the OTC Markets Group, Inc.), or (ii) if the Common Stock is not
listed on a Trading Market (other than the OTC Bulletin Board or the OTC QB, OTC QX or OTC Pink tier of the OTC Markets Group,
Inc.), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC Bulletin Board, or (iii)
if the Common Stock is not quoted on any Trading Market (other than the OTC QB, OTC QX or OTC Pink tier of the OTC Markets Group,
Inc.), a day on which the Common Stock is quoted in the over-the-counter market as reported by the OTC QB, OTC QX or OTC Pink tier
of the OTC Markets Group, Inc. (or any similar organization or agency succeeding to its functions of reporting prices); provided,
that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall
mean a Business Day.

 

“Trading Market”
means whichever of the New York Stock Exchange, the NYSE-MKT, the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq
Capital Market, the OTC Bulletin Board, the OTC QB, OTC QX or OTC Pink tier of the OTC Markets Group, Inc. (or any similar organization
or agency succeeding to its functions of reporting prices) on which the Common Stock is listed or quoted for trading on the date
in question.

 

“Transaction Documents”
means this Agreement, the Registration Rights Agreement, the annexes and exhibits attached hereto and thereto, the Irrevocable
Transfer Agent Instructions and any other documents or agreements executed in connection with the transactions contemplated hereunder.

 

“Transfer Agent”
means Manhattan Transfer Registrar Company, with a mailing address of 57 Eastwood Road, Miller Place, NY 11764, or any successor
transfer agent for the Company.

 

“Voting Debt”
has the meaning set forth in Section 3.1(g).

 

    4 

     

    

 

Article
2

PURCHASE AND SALE

 

2.1       Closing.

 

(a)            Subject
to the terms and conditions set forth in this Agreement, at the Closing, the Company shall issue and sell to each Purchaser, and
each Purchaser shall, severally and not jointly, purchase from the Company, such number of Shares of Common Stock equal to the
quotient resulting from dividing (i) the Subscription Amount for such Purchaser, as indicated opposite such Purchaser’s name
on Exhibit A hereto (the “Subscription Amount”), by (ii) the Purchase Price, rounded down
to the nearest whole Share.

 

(b)           The
Closing of the purchase and sale of the Shares shall take place at the offices of the Company on March 15, 2017 at 10:00 a.m. Eastern
Time or remotely by facsimile transmission or other electronic means or at such other location(s), date, or time as the Company
and the Purchasers holding or having the right to acquire at least a majority of the Shares to be purchased at the Closing may
mutually agree (the “Closing Date”).

 

(c)           Except
as may otherwise be agreed to among the Company and one or more of the Purchasers, on or prior to the Closing Date, each Purchaser
shall wire its Subscription Amount, in United States dollars and in immediately available funds, to a bank account designated by
the Company.

 

(d)           On
the Closing Date, upon receipt of the aggregate Purchase Price, the Company shall irrevocably instruct the Transfer Agent to deliver
to each Purchaser (within three Trading Days after the Closing) evidence of a book entry position (or, if requested in writing
by a Purchaser on or before the date hereof, a certificate), free and clear of all restrictive and other legends or instructions
(except as expressly provided in Section 4.1(b) hereof), evidencing the number of Shares such Purchaser is purchasing hereunder.

 

2.2       Closing
Deliveries.

 

(a)       On
or prior to the Closing, the Company shall issue, deliver or cause to be delivered or made available to each Purchaser the following
(the “Company Deliverables”):

 

(i)         this
Agreement, duly executed by the Company;

 

(ii)        a
legal opinion of Company Counsel dated as of the Closing Date and in substantially the form attached hereto as Exhibit D,
executed by such counsel and addressed to the Purchasers;

 

(iii)       the
Registration Rights Agreement, duly executed by the Company;

 

(iv)       a
copy of the duly executed Irrevocable Transfer Agent Instructions delivered to and acknowledged in writing by the Transfer Agent,
relating to the issuance of stock certificates, free and clear of all restrictive and other legends except as provided in Section
4.1(b) hereof, evidencing the Shares subscribed for by the Purchasers hereunder to be registered in the name of such Purchasers
as set forth on the Stock Certificate Questionnaire included as Exhibit C-2 hereto (the “Stock Certificates”)
and delivered to the Company pursuant to Section 2.2(b)(iv);

 

    5 

     

    

 

(v)        a
certificate of the Secretary of the Company (the “Secretary’s Certificate”), dated as of the Closing
Date, (a) certifying the resolutions adopted by the Board of Directors of the Company and any duly authorized committee thereof
relating to the transactions contemplated by this Agreement and the other Transaction Documents and the issuance of the Securities,
(b) certifying the current versions of the certificate of incorporation, as amended, and bylaws of the Company and (c) certifying
as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company,
in the form attached hereto as Exhibit F;

 

(vi)       a
certificate (the “Compliance Certificate”), dated as of the Closing Date and signed by the Company’s
Chief Executive Officer or its Chief Financial Officer, certifying to the fulfillment of the conditions specified in Sections 5.1(a),
(b) and (h) in the form attached hereto as Exhibit G.

 

(vii)      a
certificate evidencing the formation and good standing of the Company issued by the Secretary of State of the State of Delaware,
as of a date within five (5) days of the Closing Date; and

 

(viii)     a
certified copy of the Certificate of Incorporation, as certified by the Secretary of State of the State of Delaware, as of a date
within ten (10) days of the Closing Date.

 

(b)       On
or prior to the Closing, each Purchaser shall deliver or cause to be delivered to the Company the following (the “Purchaser
Deliverables”):

 

(i)         this
Agreement, duly executed by such Purchaser;

 

(ii)        the
Registration Rights Agreement, duly executed by such Purchaser;

 

(iii)       its
Subscription Amount, in United States dollars and in immediately available funds, by wire transfer to the account provided by the
Company no later than three (3) days before the Closing Date;

 

(iv)       a
fully completed and duly executed Selling Stockholder Questionnaire in the form attached as Annex B to the Registration Rights
Agreement;

 

(v)        a
fully completed and duly executed Accredited Investor Questionnaire in the form attached hereto as Exhibit C-1; and

 

(vi)       a
fully completed and duly executed Stock Certificate Questionnaire in the form attached hereto as Exhibit C-2.

 

(c)       On
or prior to the Closing, the Company shall deliver to Boston Scientific Corporation (“BSC”) a letter
agreement (the “Letter Agreement”), by and between the Company and BSC, in form and substance reasonably
acceptable to BSC, duly executed by the Company.

 

    6 

     

    

 

Article
3

REPRESENTATIONS AND WARRANTIES

 

3.1       Representations
and Warranties of the Company. The Company hereby represents and warrants as of the date hereof and the Closing Date (except
for the representations and warranties that speak as of a specific date, which shall be made as of such date) to each of the Purchasers
that except as disclosed in the disclosure schedule delivered by the Company hereunder (the “Disclosure Schedule”),
which disclosure shall be deemed a part of this Article 3 and shall qualify any representations and warranties made by the Company
herein to the extent of the applicable disclosure:

 

(a)       Subsidiaries.
Except as set forth on Section 3.1(a) of the Disclosure Schedule, the Company has no direct or indirect Subsidiaries other than
Corindus, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, and Corindus Security Corporation, a Delaware
corporation and wholly-owned subsidiary of the Company. The Company owns, directly or indirectly, all of the capital stock or comparable
equity interests of each Subsidiary free and clear of any and all Liens, and all the issued and outstanding shares of capital stock
or comparable equity interest of each Subsidiary are validly issued and are fully paid, non-assessable.

 

(b)       Organization
and Qualification. The Company and each Subsidiary is an entity duly incorporated, validly existing and in good standing under
the laws of the jurisdiction of its incorporation, with the requisite corporate power and authority to own or lease and use its
properties and assets and to carry on its business as currently conducted. The Company and its Subsidiaries are not in violation
of any of the provisions of their certificate of incorporation or bylaws. The Company and each of its Subsidiaries are duly qualified
to conduct business and are in good standing as a foreign corporation or other entity in each jurisdiction in which the nature
of the business conducted or property owned by them makes such qualification necessary, except where the failure to be so qualified
or in good standing, as the case may be, would not reasonably be expected to result in a Material Adverse Effect.

 

(c)       Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by each of the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and
thereunder. The execution and delivery of each of the Transaction Documents to which it is a party by the Company and the consummation
by it of the transactions contemplated hereby and thereby (including, but not limited to, the sale and delivery of the Shares)
have been duly authorized by all necessary corporate action on the part of the Company, and no further corporate action is required
by the Company, its Board of Directors or its stockholders in connection therewith other than in connection with the Required
Approvals. Each of the Transaction Documents to which it is a party has been (or upon delivery will have been) duly executed by
the Company and is, or when delivered in accordance with the terms hereof, will constitute the legal, valid and binding obligation
of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement
of, creditors’ rights and remedies or by other equitable principles of general application or insofar as indemnification
and contribution provisions may be limited by applicable law. There are no shareholder agreements, voting agreements, or other
similar arrangements with respect to the Company’s capital stock (i) to which the Company is a party or, (ii) to the Company’s
Knowledge, between or among any of the Company’s stockholders. Except as set forth on Section 3.1(c) of the Disclosure
Schedule, the Company has not entered into, and does not have any current plans to enter into, any side
letter, agreement or arrangement with any Purchaser in connection with the transactions contemplated by the Transaction Documents,
other than the Letter Agreement, and each of the Purchasers is purchasing Shares on the same terms as all other Purchasers. 

 

    7 

     

    

 

(d)       Non
Contravention. The execution, delivery and performance by the Company of the Transaction Documents to which it is a party and
the consummation by the Company of the transactions contemplated hereby or thereby (including, without limitation, the issuance
of the Shares) do not and will not (i) violate any provisions of the Company’s or its Subsidiaries’ certificate of
incorporation or bylaws, (ii) constitute a default (or an event that with notice or lapse of time or both would become a default)
under, result in the creation of any Lien upon any of the properties or assets of the Company or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any indenture, contract, lease, mortgage,
deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company
or any of its Subsidiaries is a party or bound or to which its or their property is subject or (iii) subject to the Required Approvals,
conflict with, result in a violation of, or imposition of any Lien, upon any property or assets of the Company pursuant to any
law, rule, regulation, order, judgment, injunction, decree or other restriction of any court, regulatory body, administrative agency,
governmental authority, arbitrator or other authority to which the Company or its Subsidiaries are subject (including federal and
state securities laws and regulations and the rules and regulations, assuming the correctness of the representations and warranties
made by the Purchasers herein, of any self-regulatory organization to which the Company or its securities are subject, including
all applicable Trading Markets), or by which any property or asset of the Company is bound or affected), except in the case of
clause (ii) and clause (iii) such as would not individually reasonably be expected to have a Material Adverse Effect.

 

(e)       Filings,
Consents and Approvals. The Company is not required to obtain any consent, waiver, approval, authorization or order of, qualification,
designation, declaration, give any notice to, or make any filing or registration with, any court or other federal, state, local
or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the
Transaction Documents (including the issuance of the Securities), other than (i) the filing with the Commission of one or more
Registration Statements in accordance with the requirements of the Registration Rights Agreement, (ii) filings required by applicable
state securities laws after the date hereof, (iii) the filing of a Notice of Sale of Securities on Form D with the Commission under
Regulation D of the Securities Act, (iv) the filing of any requisite notices and/or application(s) to the Principal Trading Market
for the issuance and sale of the Shares and the listing of the Shares for trading or quotation, as the case may be, thereon in
the time and manner required thereby (which will be made and approved prior to the Closing), (v) the filings required in accordance
with Section 4.6 of this Agreement and (vi) those that have been made or obtained prior to the date of this Agreement satisfying
the requirements thereof (collectively, the “Required Approvals”).

 

(f)       Issuance
of the Securities. The Shares have been duly authorized and, when issued and paid for in accordance with the terms of the Transaction
Documents, will be duly and validly issued, fully paid and non-assessable and free and clear of all Liens, other than restrictions
on transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive
or similar rights. Assuming the accuracy of the representations and warranties of the Purchasers in
this Agreement, the Shares will be issued in compliance with all applicable federal and state securities laws.

 

    8 

     

    

 

(g)       Capitalization.
The authorized capital stock of the Company consists of 250,000,000 shares of common stock and 10,000,000 shares of undesignated
preferred stock. As of the date hereof, there are no shares of preferred stock issued and outstanding and there are 119,025,221
shares of common stock issued and outstanding, of which no shares are owned by the Company. There are no other shares of any other
class or series of capital stock of the Company issued or outstanding. The Company has no capital stock reserved for issuance,
except that, as of the date hereof, there are (i) 18,263,117 shares of common stock reserved for issuance pursuant to the Company’s
stock incentive plans, of which 17,523,072 shares are issuable upon the exercise of stock options outstanding on the date hereof
and (ii) 5,083,219 shares of common stock subject to outstanding warrants. No Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents,
that have not been effectively waived as of the date hereof. Except as stated above or set forth on Section 3.1(g) of the Disclosure
Schedule, there are no bonds, debentures, notes or other indebtedness having general voting rights (or convertible into securities
having such rights) (“Voting Debt”) and no outstanding options, warrants, calls, subscriptions or other
rights, agreements, arrangements or commitments relating to the issued or unissued capital stock of the Company, obligating the
Company to issue, transfer, sell, redeem, purchase, repurchase or otherwise acquire or cause to be issued, transferred, sold, redeemed,
purchased, repurchased or otherwise acquired any capital stock or Voting Debt of, or other equity interests in, the Company or
securities or rights convertible into or exchangeable for such shares or equity interests or obligations of the Company to grant,
extend or enter into any such option, warrant, call, subscription or other right, arrangement or commitment. Except as set forth
on Section 3.1(g) of the Disclosure Schedule, the issuance and sale of the Shares will not obligate the Company to issue shares
of Common Stock or other securities to any Person (other than the Purchasers) and will not trigger any anti-dilution or price adjustment
rights. All of the outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable, have been
issued in compliance in all material respects with all applicable federal and state securities laws, and none of such outstanding
shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities which violation
would have or would reasonably be expected to result in a Material Adverse Effect. There are no registration rights, stockholders
agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company
is a party or, to the Company’s Knowledge, between or among any of the Company’s stockholders.

 

(h)       SEC
Reports. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by it under
the Exchange Act, including pursuant to Section 13, 14(a) and 15(d) thereof, (the foregoing materials, including the exhibits thereto
and documents incorporated by reference therein, being collectively referred to herein as the “SEC Reports”
and together with this Agreement, including the Disclosure Schedule hereto, each as amended and supplemented to date, the “Disclosure
Materials”), on a timely basis or has received a valid extension of such time of filing and has filed any such SEC
Reports prior to the expiration of any such extension. As of their respective filing dates (or,
if amended prior to the date of this Agreement, when amended), all SEC Reports complied in all material respects with the requirements
of the Exchange Act and the rules and regulations of the Commission promulgated thereunder. None of the SEC Reports as of their
respective dates contained any untrue statement of material fact or omitted to state a material fact required to be stated therein
or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading. There
is no transaction, arrangement, or other relationship between the Company (or any Subsidiary) and any unconsolidated or other off
balance sheet entity that is required to be disclosed by the Company in its Exchange Act filings that is not so disclosed. Each
franchise, contract or other document of a character required to be described in the SEC Reports or to be filed as an exhibit to
the SEC Reports under the Securities Act and the rules and regulations promulgated thereunder is so described or filed.

 

(i)       Financial
Statements. The consolidated financial statements of the Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the
time of filing. Such financial statements have been prepared in accordance with GAAP applied on a consistent basis during the periods
involved, except as may be otherwise specified in such financial statements or the notes thereto, and fairly present in all material
respects the consolidated financial position of the Company and its consolidated Subsidiaries taken as a whole as of and for the
dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, year-end audit adjustments. As of the date hereof, there are no disagreements between the Company and its independent
accounting firm on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure
relating to the Company’s fiscal 2016 audit or otherwise that, if not resolved to the satisfaction of the accounting firm,
would result in the accounting firm referencing such disagreement in its audit report for such fiscal year.

 

    9 

     

    

 

(j)       Tax
Matters. The Company and each of its Subsidiaries (i) has prepared and filed all foreign, federal and state income and all
other tax returns, reports and declarations required to be filed prior to the date hereof by any jurisdiction to which it is subject,
which are correct and complete in all material respects for the periods to which such tax returns relate, (ii) has paid all taxes
and other governmental assessments and charges that are material in amount, shown or determined to be due prior to the date hereof
on such returns, reports and declarations, except those being contested in good faith, with respect to which adequate reserves
have been set aside on the books of the Company and (iii) has set aside on its books provisions reasonably adequate for the payment
of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply, except where the failure
to so file or pay or set aside provisions for any such tax, assessment, charge or return would not reasonably be expected to have
a Material Adverse Effect. There are in effect no waivers of applicable statutes of limitations with respect to taxes for any year.

 

(k)       Material
Changes. Since the date of the latest balance sheet included in the financial statements contained within the SEC Reports,
(i) there have been no events, occurrences or developments that have had or would reasonably be expected to have a Material Adverse
Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade payables, accrued
expenses and other liabilities incurred in the ordinary course of business consistent with past practice and (B) liabilities not
required to be reflected in the Company’s financial statements pursuant to GAAP or to be disclosed in filings made with the
Commission, (iii) the Company has not materially altered its method of accounting or the manner in which it keeps its accounting
books and records, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders
or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock (other than in connection with
repurchases of unvested stock issued to employees of the Company), (v) the Company has not issued any equity securities to any
officer, director or Affiliate, except Common Stock issued in the ordinary course pursuant to existing Company stock option or
stock purchase plans or executive and director corporate arrangements disclosed in the SEC Reports, (vi) there has not been any
material change or amendment to, or any waiver of any material right under, any Material Contract under which the Company or any
of its assets is bound or subject, and (vii) there have not been any changes in the authorized capital, assets, liabilities, financial
condition, business or operations of the Company from that reflected in the latest financial statements contained in the SEC Reports
except changes in the ordinary course of business which have not had or would not reasonably be expected to have, either individually
or in the aggregate, a Material Adverse Effect. Except as set forth on Section 3.1(k) of the
Disclosure Schedule, (1) neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to any
law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the Company
or any Subsidiary have any knowledge or reason to believe that any of their respective creditors intend to initiate involuntary
bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do so; (2) the Company and
its Subsidiaries, individually and on a consolidated basis, are not as of the date hereof, and after giving effect to the transactions
contemplated hereby to occur at the Closing, will not be insolvent; and (3) neither the Company nor any of its Subsidiaries has
engaged in any business or in any transaction, and is not about to engage in any business or in any transaction, for which the
Company’s or such Subsidiary’s remaining assets constitute unreasonably small capital.

 

(l)       Environmental
Matters. To the Company’s Knowledge, the Company (i) is not in violation of any statute, rule, regulation, decision or
order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous
or toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances
(collectively, “Environmental Laws”), (ii) does not own or operate any real property contaminated with
any substance that is in violation of any Environmental Laws, (iii) is not liable for any off-site disposal or contamination pursuant
to any Environmental Laws, and (iv) is not subject to any claim relating to any Environmental Laws; which violation, contamination,
liability or claim has had or would have a Material Adverse Effect; and there is no pending or, to the Company’s Knowledge,
threatened investigation that might lead to such a claim. The Company and each of its Subsidiaries have received and are in compliance
with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct its business, except
where such non-compliance or failure to receive required permits, licenses or other approvals would not, individually or in the
aggregate, have or reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has
been named as a “potentially responsible party” under the Comprehensive Environmental Response, Compensation, and Liability
Act of 1980, as amended.

 

    10 

     

    

 

(m)       Litigation.
There is no Action which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction
Documents or the Securities, or (ii) would reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect. Neither the Company nor any Subsidiary, nor to the Company’s Knowledge any director or officer thereof, is or has
been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim
of breach of fiduciary duty. There has not been, and to the Company’s Knowledge there is not pending or contemplated, any
investigation by the Commission involving the Company or, to the Company’s Knowledge, any current or former director or officer
of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement
filed by the Company or any of its Subsidiaries under the Exchange Act or the Securities Act. There are no outstanding orders,
judgments, injunctions, awards or decrees of any court, arbitrator or governmental or regulatory body against the Company or, to
the Company’s Knowledge, any executive officers or directors of the Company in their capacities as such, which individually
or in the aggregate, would reasonably be expected to have a Material Adverse Effect.

 

(n)       Employment
Matters. No labor dispute exists or, to the Company’s Knowledge, is imminent with respect to any of the employees of
the Company or its Subsidiaries or any of its principal suppliers or contractors which would have a Material Adverse Effect. None
of the Company’s employees is a member of a union that relates to such employee’s relationship with the Company, and
the Company is not a party to a collective bargaining agreement.

 

(o)       Compliance.
The Company and its Subsidiaries (i) are not in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or its Subsidiaries), nor has the Company
or any of its Subsidiaries received written notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other Material Contract (whether or not such default or violation has been waived), (ii) are not
in violation of any order of any court, arbitrator or governmental body having jurisdiction over the Company, its Subsidiaries
or their properties or assets; and (iii) are in compliance with, and have not receipted notice that they are in violation of, all
statutes, laws, ordinances, rules and regulations applicable to the Company and its Subsidiaries or to the Company Products (“Applicable
Laws”), including without limitation, all applicable rules and regulations of the Food and Drug Administration (the
“FDA”), except in each case as would not, individually or in the aggregate, have a Material Adverse Effect.

 

    11 

     

    

 

(p)       Regulatory
Permits. The Company and each of its Subsidiaries possesses all licenses, certificates, approvals, permits and other authorizations
and supplements or amendments thereto issued by all applicable federal, state, local or foreign regulatory authorities necessary
to conduct their respective businesses (“Material Permits”), including,
without limitation, the FDA, such Material Permits are in full force and effect, and (i) neither the
Company nor any of its Subsidiaries has not received any notice of any adverse finding, warning letter, assertion of noncompliance
with, or adverse proceedings relating to the any such Material Permits; (ii) the Company has no Knowledge of any facts or circumstances
that the Company would reasonably expect to give rise to the revocation or modification of any Material Permits; (iii) neither
the Company nor any of its Subsidiaries has received written notice of any ongoing claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from any governmental entity or third party alleging that any product manufactured by
or on behalf of the Company or any of its Subsidiaries or out-licensed by the Company or any of its Subsidiaries (a “Company
Product”), operation or activity related to a Company Product is in violation of any Applicable Laws or a Material
Permit or has any knowledge that any such governmental entity or third party is considering any such claim, litigation, arbitration,
action, suit, investigation or proceeding; (iv) neither the Company nor any of its Subsidiaries has received written notice that
any governmental entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Material Permit
or has any knowledge that any such governmental entity has threatened or is considering such action with respect to a Company Product;
and (v) the Company and each of its Subsidiaries have filed, obtained, maintained or submitted all reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Material Permits
and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
were complete, correct and not misleading on the date filed (or were corrected or supplemented by a subsequent submission). To
the Company’s knowledge, neither the Company nor any of its Subsidiaries, directors, officers, employees or agents, has made,
or caused the making of, any false statements on, or material omissions from, any other records or documentation prepared or maintained
to comply with the requirements of the FDA or any other governmental entity.

 

(q)       Title
to Assets. The Company does not own any real property. The Company and its Subsidiaries have good and marketable title to all
tangible personal property owned by them which is material to the business of the Company and its Subsidiaries, taken as a whole,
in each case free and clear of all Liens except such as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries and except for Liens for
the payment of federal, state or other taxes for which appropriate reserves have been made in accordance with GAAP and the payment
of which is not delinquent or subject to penalties. Any real property and facilities held under lease by the Company or its Subsidiaries
are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not materially
interfere with the use made of such property and buildings by the Company or its Subsidiaries.

 

(r)       Intellectual
Property. The Company and its Subsidiaries collectively own, possess, license or have other rights to use all material foreign
and domestic patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights,
licenses, inventions, trade secrets, technology, know-how and other proprietary rights and processes necessary for the conduct
of their businesses, taken as a whole, as now conducted or as proposed in the SEC Reports to be conducted (collectively, the “Intellectual
Property”). To the Company’s Knowledge, (i) there are no rights of third parties to any Intellectual Property,
other than as licensed by the Company; (ii) the Company’s or its Subsidiaries’ use of any such Intellectual Property
in the conduct of its business as presently conducted does not infringe upon the rights of any third parties; (ii) there is no
infringement by third parties of any such Intellectual Property; (iii) there is no pending or threatened Action challenging the
Company’s rights in or to or scope of any such Intellectual Property; (iv) there is no pending or threatened Action challenging
the validity or scope of any such Intellectual Property; and (v) there is no pending or threatened Action that the Company infringes
or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of others. The Company is not
aware of any facts required to be disclosed to the U.S. Patent and Trademark Office which have not been disclosed to the U.S. Patent
and Trademark Office and which would preclude the grant of a patent in connection with any patent application of the Intellectual
Property or could form the basis of a finding of invalidity with respect to any issued patents of the Intellectual Property. The
Company and its Subsidiaries collectively have taken reasonable security measures to protect the secrecy, confidentiality and value
of all of the Intellectual Property, except where the failure to do so would not, individually or in the aggregate, have or reasonably
be expected to have a Material Adverse Effect.

 

    12 

     

    

 

(s)       Insurance.
The Company and each of its Subsidiaries is insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as are reasonable and customary in the business in which it is engaged; all policies of insurance and
fidelity or surety bonds insuring the Company and each of its Subsidiaries or their respective businesses, assets, employees, officers
and directors are in full force and effect; the Company and each of its Subsidiaries is in compliance with the terms of such policies
and instruments in all material respects; there are no claims by the Company or any of its Subsidiaries under any such policy or
instrument as to which any insurance company is denying liability or defending under a reservation of rights clause; and neither
the Company nor any of its Subsidiaries has been refused any insurance coverage sought or applied for. The Company has not received
any notice of cancellation of any such insurance, nor does the Company have any Knowledge that it will be unable to renew its existing
insurance coverage for the Company as and when such coverage expires or to obtain similar coverage from similar insurers as may
be necessary to continue its business without a significant increase in cost.

 

(t)       Transactions
with Affiliates and Employees. None of the officers or directors of the Company and, to the Company’s Knowledge, none
of the employees of the Company, is presently a party to any transaction with the Company or to a transaction presently contemplated
by the Company (other than for services as employees, officers and directors) that would be required to be disclosed by the Company
pursuant to Item 404 of Regulation S-K promulgated under the Securities Act, except as contemplated by the Transaction Documents
or set forth in the SEC Reports.

 

(u)       Internal
Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability
accountability, (iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general
or specific authorization, and (iv) the recorded accountability for assets and liabilities is compared with the existing assets
and liabilities at reasonable intervals and appropriate action is taken with respect to any differences. The Company’s internal
controls over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) are effective to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles and the Company is not aware of any material weakness in its internal controls over
financial reporting.

 

(v)       Sarbanes-Oxley.
The Company is in compliance in all material respects with all of the provisions of the Sarbanes-Oxley Act of 2002 which are applicable
to it. The Company has established disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e)
under the Exchange Act) for the Company and designed such disclosure controls and procedures to ensure that information required
to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and
reported, within the time periods specified in the Commission’s rules and forms. The Company’s certifying officers
have evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered
by the Company’s most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”).
The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers
about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date); such disclosure
controls and procedures are effective. Since the Evaluation Date, there have been no changes in the Company’s internal control
over financial reporting (as such term is defined in the Exchange Act) that have materially affected, or are reasonably likely
to materially affect, the Company’s internal control over financial reporting.

 

    13 

     

    

 

(w)       Certain
Fees. No person or entity will have, as a result of the transactions contemplated by this Agreement, any valid right, interest
or claim against or upon the Company or a Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement
or understanding entered into by or on behalf of the Company.

 

(x)       Private
Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2 of this Agreement
(without giving effect to any materiality qualifiers therein) and the accuracy of the information disclosed by each Purchaser in
the Accredited Investor Questionnaire delivered pursuant to Section 2.2(b)(iv) and Section 5.3(d), no registration under the Securities
Act is required for the offer and sale of the Securities by the Company to the Purchasers under the Transaction Documents.

 

(y)       No
General Solicitation. Neither the Company nor any Person acting on its behalf has conducted any “general solicitation”
or “general advertising” (as those terms are used in Regulation D) in connection with the offer or sale of any of the
Securities.

 

(z)       No
Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2
(without giving effect to any materiality qualifiers therein), neither the Company nor any Person acting on its behalf has, directly
or indirectly, at any time within the past six (6) months, made any offers or sales of any Company security or solicited any offers
to buy any security under circumstances that would (i) eliminate the availability of the exemption from registration under Section
4(a)(2) or Regulation D under the Securities Act in connection with the offer and sale by the Company of the Securities as contemplated
hereby or (ii) cause the Offering of the Securities pursuant to the Transaction Documents to be integrated with prior offerings
by the Company for purposes of any applicable law, regulation or shareholder approval provisions, including, without limitation,
under the rules and regulations of any Trading Market on which any of the securities of the Company are listed or designated.

 

(aa)    Registration Rights.
Other than the Purchasers pursuant to the Registration Rights Agreement or as disclosed in Section 3.1(aa) of the Disclosure
Schedule, no Person has any right to cause the Company to effect the registration under the Securities Act of any securities of
the Company.

 

(bb)    Listing and Maintenance
Requirements. The Company’s Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Company
has taken no action designed to terminate the registration of the Common Stock under the Exchange Act, nor has the Company received
any notification that the Commission is contemplating terminating such registration. There are no proceedings pending or, to the
Company’s Knowledge, threatened against the Company relating to the continued listing of the Company’s common stock
on the Principal Trading Market and the Company has not, in the 12 months preceding the date hereof, received written notice from
any Trading Market on which the Common Stock is listed or quoted to the effect that the Company is not in compliance with the listing
or maintenance requirements of such Trading Market. The Company is in compliance with all listing and maintenance requirements
of the Principal Trading Market on the date hereof and the issuance of the Securities will not violate any such listing or maintenance
requirements.

 

(cc)     Application of Takeover
Protections; Rights Agreements. The Company and its board of directors have taken all necessary action, if any, in order to
render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Company’s charter documents or the laws of the State of Delaware
that is or could reasonably be expected to become applicable to any of the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including, without limitation, the Company’s
issuance of the Securities and the Purchasers’ ownership of the Securities. The Company has not adopted a stockholder rights
plan or similar arrangement relating to accumulations of beneficial ownership of Common Stock or a change in control of the Company.

 

    14 

     

    

 

(dd)     Off Balance Sheet
Arrangements. There is no transaction, arrangement, or other relationship between the Company and an unconsolidated or other
off balance sheet entity that is required to be disclosed by the Company in its SEC Reports (including, for purposes hereof, any
that are required to be disclosed in a Form 10) and is not so disclosed or that otherwise would have a Material Adverse Effect.

 

(ee)     Foreign Corrupt Practices.
Neither the Company nor any of its Subsidiaries, nor to the Company’s Knowledge, any agent or other person acting on behalf
of the Company or its Subsidiaries, has: (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment
or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic
government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed
to disclose fully any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware)
which is in violation of law or (iv) taken any action, directly or indirectly, that would result in a violation by the Company
or such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder.

 

(ff)     Money Laundering Laws.
The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial
recordkeeping and reporting requirements and the money laundering statutes and the rules and regulations thereunder and any related
or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money
Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body
or any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to
the Knowledge of the Company, threatened.

 

(gg)     OFAC. Neither
the Company nor any of its Subsidiaries nor, to the Knowledge of the Company, any director, officer, agent or employee of the Company
or any of its Subsidiaries (i) is currently subject to any sanctions administered or imposed by the United States (including any
administered or enforced by the Office of Foreign Assets Control of the U.S. Treasury Department, the U.S. Department of State,
or the Bureau of Industry and Security of the U.S. Department of Commerce), the United Nations Security Council, the European Union,
or the United Kingdom (including sanctions administered or controlled by Her Majesty’s Treasury) (collectively, “Sanctions”
and such persons, “Sanction Persons”) or (ii) will, directly or indirectly, use the proceeds of this
offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person
in any manner that will result in a violation of any economic Sanctions by, or could result in the imposition of Sanctions against,
any person (including any person participating in the offering, whether as underwriter, advisor, investor or otherwise). Neither
the Company nor any of its Subsidiaries nor, to the Knowledge of the Company, any director, officer, agent, or employee of the
Company or any of its Subsidiaries, is a person that is, or is 50% or more owned or otherwise controlled by a person that is: (i)
the subject of any Sanctions; or (ii) located, organized or resident in a country or territory that is, or whose government is,
the subject of Sanctions that broadly prohibit dealings with that country or territory (currently, Cuba, Iran, North Korea, Sudan,
and Syria) (collectively, “Sanctioned Countries” and each, a “Sanctioned Country”).
Neither the Company nor any of its Subsidiaries has engaged in any dealings or transactions with or for the benefit of a Sanctioned
Person, or with or in a Sanctioned Country, in the preceding three years, nor does the Company or its Subsidiaries have any plans
to increase their respective dealings or transactions with Sanctioned Persons, or with or in Sanctioned Countries.

 

    15 

     

    

 

(hh)     Transfer
Taxes. There are no transfer taxes or other similar fees or charges under Federal law or the laws of any state, or any political
subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement or the issuance by the
Company or sale by the Company of the Securities. 

 

(ii)     Investment
Company. The Company is not and, after giving effect to the offering and sale of the Securities, will not be an “investment
company” as defined in the Investment Company Act of 1940, as amended.

 

(jj)     Price of Common Stock.
The Company has not, and to the Company’s Knowledge no one acting on its behalf has, taken, directly or indirectly, any action
designed to cause or result in, or that has constituted or that might reasonably be expected to constitute the stabilization or
manipulation of the price of any securities of the Company to facilitate the sale or resale of the Securities.

 

(kk)     ERISA. None of
the following events has occurred or exists: (i) a failure to fulfill the obligations, if any, under the minimum funding standards
of Section 302 of the United States Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
and the regulations and published interpretations thereunder with respect to a Plan that is required to be funded, determined without
regard to any waiver of such obligations or extension of any amortization period; (ii) an audit or investigation by the Internal
Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other federal or state governmental
agency or any foreign regulatory agency with respect to the employment or compensation of employees by any of the Company that
would reasonably be expected to have a Material Adverse Effect; (iii) any breach of any contractual obligation, or any violation
of law or applicable qualification standards, with respect to the employment or compensation of employees by the Company that would
reasonably be expected to have a Material Adverse Effect. None of the following events has occurred or is reasonably likely to
occur: (i) a material increase in the aggregate amount of contributions required to be made to all Plans in the current fiscal
year of the Company compared to the amount of such contributions made in the most recently completed fiscal year of the Company;
(ii) a material increase in the “accumulated post-retirement benefit obligations” (within the meaning of Statement
of Financial Accounting Standards 106) of the Company compared to the amount of such obligations in the most recently completed
fiscal year of the Company; (iii) any event or condition giving rise to a liability under Title IV of ERISA that would reasonably
be expected to have a Material Adverse Effect; or (iv) the filing of a claim by one or more employees or former employees of the
Company related to their employment that would reasonably be expected to have a Material Adverse Effect. For purposes of this paragraph,
the term “Plan” means a plan (within the meaning of Section 3(3) of ERISA) subject to Title IV of ERISA with respect
to which the Company may have any liability.

 

(ll)     No “Bad Actor”
Disqualification. The Company has conducted a factual inquiry including the procurement of relevant questionnaires from each
Covered Person (as defined below) or other means to determine whether any Covered Person (as defined below) is subject to any of
the “bad actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (“Disqualification
Events”). To the Company’s knowledge, after conducting such factual inquiries, no Covered Person is subject
to a Disqualification Event, except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act.
The Company has complied, to the extent applicable, with any disclosure obligations under Rule 506(e) under the Securities Act.
“Covered Persons” are those persons specified in Rule 506(d)(1) under the Securities Act, including the
Company; any predecessor or affiliate of the Company; any director, executive officer, other officer participating in the offering,
general partner or managing member of the Company; any beneficial owner of 20% or more of the Company’s outstanding voting
equity securities, calculated on the basis of voting power; any promoter (as defined in Rule 405 under the Securities Act) connected
with the Company in any capacity at the time of the sale of the Shares; and any person that has been or will be paid (directly
or indirectly) remuneration for solicitation of purchasers in connection with the sale of the Shares (a “Solicitor”),
any general partner or managing member of any Solicitor, and any director, executive officer or other officer participating in
the offering of any Solicitor or general partner or managing member of any Solicitor.

 

    16 

     

    

 

(mm)     Registration Eligibility.
To the Company’s knowledge, the Company is eligible to register the resale of the Shares by the Purchasers using Form S-3
promulgated under the Securities Act.

 

(nn)     Shell Company Status.
Except as set forth in Section 3(nn) of the Disclosure Schedule, the Company is not, and has never been, an issuer identified in
Rule 144(i)(1).

 

(oo)     Disclosure.
The Company understands and confirms that the Purchasers will rely on the foregoing representations in effecting transactions in
securities of the Company. To the Knowledge of the Company, (i) the Disclosure Materials, and all due diligence materials regarding
the Company, its business and the transactions contemplated hereby that are not projections or forward-looking statements, furnished
by or on behalf of the Company to any Purchaser in connection with such Purchaser’s evaluation of the Company are, when taken
together with the Disclosure Materials, true and correct in all material respects and do not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances
under which they were made, not misleading. To the Knowledge of the Company, all projections and forward-looking statements regarding
the Company and its business, furnished by or on behalf of the Company to any Purchaser in connection with such Purchaser’s
evaluation of the Company, were made on a good faith, reasonable basis by Company management.

 

3.2       Representations
and Warranties of the Purchasers. Each Purchaser hereby, for itself and for no other Purchaser, represents and warrants as
of the date hereof and as of the Closing Date to the Company as follows:

 

(a)       Organization;
Authority. Such Purchaser is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization with the requisite corporate, partnership, limited liability company or other similar power and authority to
enter into and to consummate the transactions contemplated by the Transaction Documents to which it is a party and otherwise to
carry out its obligations hereunder and thereunder. The execution, delivery and performance by such Purchaser of the transactions
contemplated by this Agreement have been duly authorized by all necessary corporate or, if such Purchaser is not a corporation,
such partnership, limited liability company or other applicable like action, on the part of such Purchaser. Each Transaction Document
to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms
hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its
terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation
or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable
principles of general application or insofar as indemnification and contribution provisions may be limited by applicable law.

 

    17 

     

    

 

(b)       Non
Contravention. The execution, delivery and performance by such Purchaser of the Transaction Documents to which it is a party
and the consummation by such Purchaser of the transactions contemplated hereby and thereby will not (i) result in a violation of
the organizational documents of such Purchaser, (ii) constitute a default (or an event which with notice or lapse of time or both
would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement,
indenture or instrument to which such Purchaser is a party or (iii) result in a violation of any law, rule, regulation, order,
judgment or decree (including federal and state securities laws) applicable to such Purchaser, except in the case of clauses (ii)
and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably
be expected to have a material adverse effect on the ability of such Purchaser to perform its obligations hereunder.

 

(c)       Investment
Intent. Such Purchaser understands that the Securities are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account
and not with a view to, or for distributing or reselling such Securities or any part thereof in violation of the Securities Act
or any applicable state securities laws. Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.
Such Purchaser does not presently have any agreement, plan or understanding, directly or indirectly, with any Person to distribute
or effect any distribution of any of the Securities (or any securities which are derivatives thereof) to or through any person
or entity; such Purchaser is not a registered broker-dealer under Section 15 of the Exchange Act or an entity engaged in a business
that would require it to be so registered as a broker-dealer.

 

(d)       Purchaser
Status. At the time such Purchaser was offered the Securities, it was, and at the date hereof it is, an “accredited investor”
as defined in Rule 501(a) under the Securities Act, for the reason(s) specified on the Accredited Investor Questionnaire attached
hereto as completed by such Purchaser, and such Purchaser shall submit to the Company such further assurances of such status as
may be reasonably requested by the Company.

 

(e)       General
Solicitation. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented
at any seminar or any other general advertisement.

 

(f)       Experience
of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

 

(g)       Access
to Information. Such Purchaser acknowledges that it has had the opportunity to review the Disclosure Materials and has been
afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives
of the Company concerning the terms and conditions of the Offering of the Securities and the merits and risks of investing in the
Securities; (ii) access to information about the Company and its respective financial condition, results of operations, business,
properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such
additional information that the Company possesses or can acquire without unreasonable effort or expense
that is necessary to make an informed investment decision with respect to the investment. Neither such inquiries nor any other
investigation conducted by or on behalf of such Purchaser or its representatives or counsel shall
modify, amend or affect such Purchaser’s right to rely on the truth, accuracy and completeness
of the Disclosure Materials and the Company’s representations and warranties contained in the Transaction Documents (as qualified
by the Disclosure Materials). Such Purchaser has sought such accounting, legal and tax advice as it has considered necessary to
make an informed decision with respect to its acquisition of the Securities.

 

    18 

     

    

 

(h)      Certain
Trading Activities. Other than with respect to the transactions contemplated herein, since the time such Purchaser was first
contacted by the Company or any other Person regarding the transactions contemplated hereby, neither such Purchaser nor any Affiliate
of such Purchaser (including, for purposes of this Section 3.2(h), any limited partner of such Purchaser) has, directly or indirectly,
nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser or an Affiliate of such Purchaser,
effected or agreed to effect any transactions in the securities of the Company (including, without limitation, any Short Sales
involving the Company’s securities). Neither such Purchaser nor any Affiliate of such Purchaser holds any short position
in the Company’s securities. Other than to other Persons party to this Agreement or to employees or advisors of such Purchaser,
such Purchaser has maintained the confidentiality of all disclosures made to it in connection with the transactions contemplated
hereby (including the existence and terms of such transactions).

 

(i)       Brokers
and Finders. No Person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest
or claim against or upon the Company or any Purchaser for any commission, fee or other compensation pursuant to any agreement,
arrangement or understanding entered into by or on behalf of such Purchaser.

 

(j)       Independent
Investment Decision. Such Purchaser has independently evaluated the merits of its decision to purchase Securities pursuant
to the Transaction Documents, and such Purchaser confirms that it has not relied on the advice of any other Person’s business
and/or legal counsel in making such decision. Such Purchaser understands that nothing in this Agreement or any other materials
presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Securities constitutes legal,
tax or investment advice. Such Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has
deemed necessary or appropriate in connection with its purchase of the Securities.

 

(k)      Reliance
on Exemptions. Such Purchaser understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon
the truth and accuracy of, and such Purchaser’s compliance with, the representations, warranties, agreements, acknowledgements
and understandings of such Purchaser set forth herein in order to
determine the availability of such exemptions and the eligibility of such Purchaser to acquire
the Securities.

 

(l)       No
Governmental Review. Such Purchaser understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment
in the Securities nor have such authorities passed upon or endorsed the merits of the Offering of the Securities.

 

(m)     Regulation
M. Such Purchaser is aware that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of Common
Stock and other activities with respect to the Common Stock by the Purchasers.

 

(n)      Residency.
Such Purchaser’s principal executive offices are in the jurisdiction set forth immediately below such Purchaser’s name
on the signature page attached hereto.

 

    19 

     

    

 

(q)       Prohibited
Purchaser. Such Purchaser represents that neither it nor, to its knowledge, any person or entity controlling, controlled by
or under common control with it, nor any person having a beneficial interest in it, nor any person on whose behalf the Purchaser
is acting: (i) is a person listed in the Annex to Executive Order No. 13224 (2001) issued by the President of the United States
(Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism);
(ii) is named on the List of Specially Designated Nationals and Blocked Persons maintained by the U.S. Office of Foreign Assets
Control; (iii) is a non-U.S. shell bank or is providing banking services indirectly to a non-U.S. shell bank; (iv) is a senior
non-U.S. political figure or an immediate family member or close associate of such figure; or (v) is otherwise prohibited from
investing in the Company pursuant to applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations,
rules or orders (categories (i) through (v), each a “Prohibited Purchaser”). The Purchaser agrees to
provide the Company, promptly upon request, all information that the Company reasonably deems necessary or appropriate to comply
with applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations, rules and orders. The Purchaser
consents to the disclosure to U.S. regulators and law enforcement authorities by the Company and its Affiliates and agents of such
information about the Purchaser as the Company reasonably deems necessary or appropriate to comply with applicable U.S. antimony
laundering, anti-terrorist and asset control laws, regulations, rules and orders. If the Purchaser is a financial institution that
is subject to the USA Patriot Act, the Purchaser represents that it has met all of its obligations under the USA Patriot Act. The
Purchaser acknowledges that if, following its investment in the Company, the Company reasonably believes that the Purchaser is
a Prohibited Purchaser, the Company has the right or may be obligated to prohibit additional investments, segregate the assets
constituting the investment in accordance with applicable regulations or immediately require the Purchaser to transfer the Shares.
The Purchaser further acknowledges that the Purchaser will have no claim against the Company or any of its Affiliates or agents
for any form of damages as a result of any of the foregoing actions.

 

The Company and each of the
Purchasers acknowledge and agree that no party to this Agreement has made or makes any representations or warranties with respect
to the transactions contemplated hereby other than those specifically set forth in this Article III and the Transaction Documents
and that, except as otherwise provided herein, neither the Company nor any Purchaser has relied on the accuracy or completeness
of any information not contained in the Transaction Documents.

 

Article
4

OTHER AGREEMENTS OF THE PARTIES

 

4.1       Transfer
Restrictions.

 

(a)       Compliance
with Laws. Notwithstanding any other provision of the Transaction Documents, each Purchaser covenants that the Securities may
be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities
Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the Securities
Act, and in compliance with any applicable state and federal securities laws. In connection with any transfer of the Securities
other than (i) pursuant to an effective registration statement, (ii) to the Company, (iii) pursuant to Rule 144, or (iv) in connection
with a bona fide pledge, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected
by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory
to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities
Act, and, as a condition of such transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement
and shall have the rights of a Purchaser under this Agreement and the Registration Rights Agreement.

 

(b)       Legends.
Certificates evidencing the Securities shall bear any legend as required by the “Blue Sky” laws of any state and a
restrictive legend in substantially the following form until such time as they are not required under Section 4.1(c) (and a stock
transfer order may be placed against transfer of the certificates for the Securities):

 

    20 

     

    

 

THESE SECURITIES HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES
LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY.

 

In addition, if the Company
reasonably determines that any Purchaser is an Affiliate of the Company, the certificate evidencing the Securities issued to such
Purchaser shall bear a customary “Affiliates” legend.

 

(c)       Removal
of Legends. Subject to the Company’s right to request an opinion of counsel as set forth in Section 4.1(a), the legend
set forth in Section 4.1(b) above shall be removable and the Company shall issue or cause to be issued a certificate without such
legend or any other legend to the holder of the applicable Shares upon which it is stamped or issue or cause to be issued to such
holder by electronic delivery at the applicable balance account at The Depository Trust Company (“DTC”)
as provided in this Section 4.1(c), if (i) such Securities are registered for resale under the Securities Act and the Purchaser
is selling pursuant to the effective registration statement registering the Securities for resale (provided that, the Purchaser
agrees to only sell such Securities during such time that such registration statement is effective and not withdrawn or suspended,
and only as permitted by such registration statement), or (ii) such Securities are sold or transferred in compliance with Rule
144 (if the transferor is not an Affiliate of the Company), including without limitation in compliance with the current public
information requirements of Rule 144 if applicable to the Company at the time of such sale or transfer, and the holder and its
broker have delivered customary documents reasonably requested by the Transfer Agent and/or Company Counsel in connection with
such sale or transfer. Any fees (with respect to the Transfer Agent, Company Counsel or otherwise) associated with the removal
of such legend shall be borne by the Company. Following the Effective Date (as defined in the Registration Rights Agreement), or
at such other time as a legend is no longer required for certain Securities, the Company will no later than three (3) Trading Days
following the delivery by a Purchaser to the Company or the Transfer Agent (with concurrent notice and delivery of copies to the
Company) of a legended certificate representing such Shares (endorsed or with stock powers attached, signatures guaranteed, and
otherwise in form necessary to affect the reissuance and/or transfer, and together with such other customary documents as the Transfer
Agent and/or Company Counsel shall reasonably request), deliver or cause to be delivered to the transferee of such Purchaser or
such Purchaser, as applicable, a certificate representing such Securities that is free from all restrictive and other legends.
Certificates for Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchasers, as applicable,
by crediting the account of the transferee’s or Purchaser’s prime broker with DTC.

 

(d)       Irrevocable
Transfer Agent Instructions. The Company shall issue irrevocable instructions to its Transfer Agent, and any subsequent Transfer
Agent, in the form of Exhibit E attached hereto (the “Irrevocable Transfer Agent Instructions”).
The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions or instructions
consistent therewith or otherwise contemplated hereby or thereby or by the other Transaction Documents or such other documents
as the Transfer Agent may request in connection with any such instructions will be given by the Company to its Transfer Agent in
connection with this Agreement, and that the Securities shall otherwise be freely transferable on the books and records of the
Company as and to the extent provided in and subject to the terms of this Agreement, the other Transaction Documents and applicable
law.

 

    21 

     

    

 

(e)       Acknowledgement.
While the Registration Statement remains effective, each Purchaser hereunder may sell the Shares in accordance with the plan of
distribution contained in the Registration Statement and, if it does so, it will comply therewith and with the related prospectus
delivery requirements unless an exemption therefrom is available. Each Purchaser, severally and not jointly with the other Purchasers,
agrees that if it is notified by the Company in writing at any time that the Registration Statement
registering the resale of the Shares is not effective or that the prospectus included in such Registration Statement no longer
complies with the requirements of Section 10 of the Securities Act, such Purchaser will refrain from selling such Shares until
such time as such Purchaser is notified by the Company that such Registration Statement is effective or such prospectus is compliant
with Section 10 of the Securities Act, unless such Purchaser is able to, and does, sell such
Shares pursuant to an available exemption from the registration requirements of Section 5 of the Securities Act. Each Purchaser
acknowledges that the delivery of the Irrevocable Transfer Agent Instructions and any removal of any legends from certificates
representing the Shares as set forth in this Section 4.1 is predicated on the Company’s reliance upon the Purchaser’s
acknowledgement in this Section 4.1(e).

 

4.2       Acknowledgment
of Dilution. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares
of Common Stock. The Company further acknowledges that its obligations under the Transaction Documents, including without limitation
its obligation to issue the Shares pursuant to the Transaction Documents, are, subject to the terms and conditions expressly set
forth in this Agreement, unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction,
regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive
effect that such issuance may have on the ownership of the other stockholders of the Company.

 

4.3       Form
D and Blue Sky. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and
to provide a copy thereof to each Purchaser who requests a copy in writing promptly after such filing. The Company shall take such
action as the Company shall reasonably determine is necessary in order to qualify the Securities for sale to the Purchasers at
the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws of the states of the United States
(or to obtain an exemption from such qualification), which, subject to the accuracy of the Company’s and the Purchaser’s
representations and warranties set forth herein, shall consist of the submission of all filings and reports relating to the offer
and sale of the Securities pursuant to Rule 506 of Regulation D required under applicable securities or “Blue Sky”
laws of the states of the United States following the Closing Date, and shall provide evidence of any such action so taken to the
Purchasers who request in writing such evidence.

 

4.4       No
Integration. The Company shall not, and shall use its commercially reasonable efforts to ensure that the Affiliates of the
Company shall not, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that will be integrated with the offer or sale of the Securities in a manner that would require
the registration under the Securities Act of the sale of the Securities to the Purchasers, or that will be integrated with the
offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder
approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent
transaction.

 

    22 

     

    

 

4.5       Indemnification.

 

(a)       Indemnification
of the Purchasers. In addition to the indemnity provided in the Registration Rights Agreement, subject to this Section 4.8,
the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and
agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such
title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and
Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other
Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title)
of such controlling Person (each, a “Purchaser Party”) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs
and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur, as a result
of or relating to: (1) third party claims against such Purchaser relating to any breach of any of the representations, warranties,
covenants or agreements made by the Company in this Agreement or in the other Transaction Documents, and (2) third party claims
against a Purchaser or any of its Affiliates, in any capacity, by any Person who is not an Affiliate, limited partner, or other
investor of such Purchaser, with respect to any of the transactions contemplated by the Transaction Documents (unless such action
is based upon a breach of such Purchaser’s representations, warranties or covenants under the Transaction Documents or any
conduct by such Purchaser which constitutes fraud, gross negligence, willful misconduct or malfeasance). The Company will not be
liable to any Purchaser Party under this Agreement to the extent, but only to the extent that a loss, claim, damage or liability
is attributable to (i) the failure of such Purchaser Party to comply with the covenants and agreements contained in Section 4.8
below respecting sale of the Securities, (ii) the inaccuracy of any representations made by such Purchaser Party herein, or (iii)
information regarding such Purchaser Party furnished in such Purchaser Party’s Accredited Investor Questionnaire to the Company
by such Purchaser Party.

 

(b)       Conduct
of Indemnification Proceedings. Promptly after receipt by any Person (the “Indemnified Person”)
of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding
or investigation in respect of which indemnity may be sought pursuant to Section 4.8(a), such Indemnified Person shall promptly
notify the Company in writing and the Company shall have the right to assume the defense thereof, including the employment of counsel
reasonably satisfactory to such Indemnified Person and the assumption of the payment of all fees and expenses; provided, however,
that the failure of any Indemnified Person to so notify the Company shall not relieve the Company of its obligations hereunder
except to the extent that the Company is actually and materially prejudiced by such failure to notify. In any such proceeding,
any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the
expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to the retention
of such counsel; (ii) the Company shall have failed promptly to assume the defense of such proceeding or the Company does not,
upon assuming the defense of such proceeding, conduct the defense of such claim actively and diligently; or (iii) the named parties
to any such proceeding (including any impleaded parties) include both such Indemnified Person and the Company, and such Indemnified
Person shall have been advised by counsel that a conflict of interest exists if the same counsel were to represent such Indemnified
Person and the Company; (iv) the claim is based upon any proceeding, indictment, allegation or investigation of a criminal nature;
or (v) the claim seeks an injunction or non-monetary or equitable relief against the Indemnified Person, other than any such claim
that is incidental to the primary claim or claims and not material (in the case of clauses (ii)-(v), if such Indemnified Party
notifies the Company in writing that it elects to employ separate counsel at the expense of the Company, the Company shall not
have the right to assume the defense thereof and such counsel shall be at the expense of the Company). The Company shall not be
liable for any settlement of any proceeding effected without its written consent, which consent shall not be unreasonably withheld,
delayed or conditioned. Without the prior written consent of the Indemnified Person, which consent shall not be unreasonably withheld,
delayed or conditioned, the Company shall not effect any settlement of any pending or threatened proceeding in respect of which
any Indemnified Person is a party, unless such settlement includes an unconditional release of such
Indemnified Person from all liability arising out of such Proceeding and such settlement does not require any Indemnified Person
to perform any covenant or refrain from engaging in any activity or include any non-monetary limitation on the actions of any Indemnified
Person or any of its Affiliates or any admission of fault, violation, culpability, malfeasance or nonfeasance by, or on behalf
of, or liability on behalf of, any such Indemnified Person.

 

    23 

     

    

 

4.6       Listing
of Securities. In the time and manner required by the Principal Trading Market, the Company shall have prepared and filed with
and, by the date hereof, shall have obtained, the approval of such Trading Market any additional shares listing application that
may be required by such Trading Market covering all of the Shares and shall use its commercially reasonable efforts to take all
steps necessary to maintain, so long as any other shares of Common Stock shall be so listed, such listing.

 

4.7       Securities
Laws Disclosure; Publicity. On or before 9:00 a.m., New York City time, on the Business Day immediately following the date
hereof, the Company shall issue a press release (the “Press Release”) reasonably acceptable to the Purchasers
disclosing all material terms of the transactions contemplated hereby. On or before 5:30 p.m., New York City time, on the fourth
Trading Day immediately following the execution of this Agreement, the Company will file a Current Report on Form 8-K with the
Commission describing the terms of the Transaction Documents (and including as exhibits to such Current Report on Form 8-K the
material Transaction Documents (including, without limitation, this Agreement and the Registration Rights Agreement)). Each Purchaser,
severally and not jointly with the other Purchasers, covenants that it will comply with the provisions of any confidentiality or
nondisclosure agreement executed by it and, in addition, until such time as the transactions contemplated by this Agreement are
required to be publicly disclosed by the Company as described in this Section 4.7, such Purchaser will maintain the confidentiality
of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). In addition,
except as otherwise required by law or applicable stock exchange rules, no announcement or other disclosure, public or otherwise,
shall be made, either directly or indirectly, by the Company or its Affiliates that mentions or references BSC or its Affiliates
without the prior written consent of BSC, which consent shall not be unreasonably withheld, delayed or conditioned.

 

4.8       Dispositions
and Confidentiality after the Date Hereof. Each Purchaser shall not, and shall cause any Affiliate of such Purchaser which
(i) had knowledge of the transactions contemplated hereby, (ii) has or shares discretion relating to such Purchaser’s investments
or trading or information concerning such Purchaser’s investments, including in respect of the Securities and (iii) is subject
to such Purchaser’s review or input concerning such Affiliate’s investments or trading (collectively, “Trading
Affiliates”) not to, prior to the effectiveness of the Registration Statement: (a) sell, offer to sell, solicit offers
to buy, dispose of, loan, pledge or grant any right with respect to (collectively, a “Disposition”) the
Securities; or (b) engage in any hedging or other transaction which is designed or could reasonably be expected to lead to or result
in a Disposition of the Securities by such Purchaser or a Trading Affiliate, except, in each case, for Dispositions pursuant to
an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, and in compliance
with any applicable state and federal securities laws. During the 12-month period immediately following the date hereof, no Purchaser
shall, and each Purchaser shall cause its Trading Affiliates not to, engage in any Short Sales or hedging transactions involving
the Company’s securities. In addition, each Purchaser agrees that for so long as it owns any Common Stock, it will not enter
into any Short Sale of Shares executed at a time when such Purchaser has no equivalent offsetting long position in the Common Stock.
For purposes of determining whether such Purchaser has an equivalent offsetting long position in the Common Stock, shares that
such Purchaser is entitled to receive within sixty (60) days (whether pursuant to contract or upon conversion or exercise of convertible
securities) will be included as if held long by such Purchaser. Each Purchaser covenants that neither it nor any Person acting
on its behalf or pursuant to any understanding with it will engage in any transactions in the Company’s securities (including,
without limitation, any Short Sales involving the Company’s securities) during the period from the date hereof until the
earlier of such time as (i) the transactions contemplated by this Agreement are first publicly announced as described in Section
4.7 or (ii) this Agreement is terminated in full pursuant to Section 6.17. Each Purchaser understands and acknowledges, severally
and not jointly with any other Purchaser, that the Commission currently takes the position that covering a short position established
prior to effectiveness of a resale registration statement with shares included in such registration statement would be a violation
of Section 5 of the Securities Act, as set forth in Division of Corporation Financing Compliance and Disclosure Interpretation
239.10 regarding short selling.

 

    24 

     

    

 

4.9       Shelf
Registration; Authorized Shares. The Company shall use its commercially reasonable efforts to ensure that it has enough authorized
shares of Common Stock and an effective shelf registration statement under the Securities Act to access the equity capital markets
from time to time after the Closing should it be necessary or advisable to do so.

 

Article
5

CONDITIONS PRECEDENT TO CLOSING

 

5.1       Conditions
Precedent to the Obligations of the Purchasers to Purchase Securities at the Closing. The obligation of each Purchaser to acquire
Securities at the Closing is subject to the fulfillment, on or prior to the Closing Date, of each of the following conditions,
any of which may be waived by such Purchaser (as to itself only):

 

(a)       Representations
and Warranties. The representations and warranties made by the Company in Section 3.1 shall be true and correct in all material
respects (except for those representations and warranties which are qualified as to materiality, in which case such representations
and warranties shall be true and correct in all respects) as of the date when made and as of the Closing
Date, as though made on and as of such date, except for such representations and warranties that speak as of a different specified
date.

 

(b)       Performance.
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing.

 

(c)       No
Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.

 

(d)       Consents.
The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary
for consummation of the purchase and sale of the Securities at the Closing (including all Required Approvals, except for those
set forth in clauses (i), (ii) and (iii) of Section 3.1(e), which may be obtained after the Closing), all of which shall be and
remain so long as necessary in full force and effect.

 

(e)       No
Suspensions of Trading in Common Stock. The Common Stock shall not have been suspended, as of the Closing Date, by the Commission.

 

(f)       Company
Deliverables. The Company shall have delivered the Company Deliverables in accordance with Section 2.2(a).

 

    25 

     

    

 

(g)       Termination.
This Agreement shall not have been terminated in accordance with Section 6.17 herein.

 

(h)       No
Adverse Events.

 

(i)         Neither
the Company nor any of its Subsidiaries shall have taken any steps to seek protection pursuant to any law or statute relating to
bankruptcy, insolvency, reorganization, receivership, liquidation or winding up.

 

(ii)        Neither
the Company nor any of its Subsidiaries shall have received any notice from their respective creditors that such creditors intend
to (A) initiate involuntary bankruptcy proceedings or (B) accelerate any amounts owing from the Company or any of its Subsidiaries
to such creditor.

 

(iii)       Neither
the Company nor any of its Subsidiaries, individually and on a consolidated basis, shall be insolvent.

 

(iv)        Except
as set forth in Section 3.1(k) of the Disclosure Schedule, neither the Company nor any of its Subsidiaries shall have engaged in
any business or in any transaction, and shall not be about to engage in any business or in any transaction, for which the Company’s
or such Subsidiary’s remaining assets constitute unreasonably small capital.

 

5.2       Conditions
Precedent to the Obligations of BSC to Purchase Securities at the Closing. The obligation of BSC to acquire Securities at the
Closing is subject to the fulfillment, on or prior to the Closing Date, of the Company having executed and delivered the Letter
Agreement to BSC, which condition may be waived by BSC.

 

5.3       Conditions
Precedent to the Obligations of the Company to sell Securities at the Closing. The Company’s obligation to sell and issue
the Securities to each Purchaser at the Closing is subject to the fulfillment on or prior to the Closing Date of the following
conditions, any of which may be waived by the Company:

 

(a)       Representations
and Warranties. The representations and warranties made by such Purchaser in Section 3.2 hereof shall be true and correct in
all material respects (except for those representations and warranties which are qualified as to materiality, in which case such
representations and warranties shall be true and correct in all respects) as of the date when made, and as of the Closing Date
as though made on and as of such date, except for representations and warranties that speak as of a different specified date.

 

(b)       Performance.
Such Purchaser shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by such Purchaser at or prior to the Closing
Date.

 

(c)       No
Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation
of any of the transactions contemplated by the Transaction Documents.

 

(d)       Purchaser
Deliverables. Such Purchaser shall have delivered its Purchaser Deliverables in accordance with Section 2.2(b).

 

    26 

     

    

 

(e)       Consents.
Such Purchaser shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary
from any governmental authorities necessary for consummation of the purchase and sale of the Securities at the Closing.

 

(f)       Termination.
This Agreement shall not have been terminated in accordance with Section 6.17 herein.

 

Article
6

MISCELLANEOUS

 

6.1       Fees
and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, the Company and the Purchasers shall
each pay the fees and expenses of their respective advisers, counsel, accountants and other experts, if any, and all other expenses
incurred by such party in connection with the negotiation, preparation, execution, delivery and performance of this Agreement.
The Company shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection
with the sale and issuance of the Securities to the Purchasers.

 

6.2       Entire
Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter thereof and supersede all prior agreements, understandings, discussions and representations,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and
schedules. At or after the Closing, and without further consideration, the Company and the Purchasers will execute and deliver
to the other such further documents as may be reasonably requested in order to give practical effect to the intention of the parties
under the Transaction Documents.

 

6.3       Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number specified in this Section prior to 5:00 p.m., Boston time, on a Trading Day, (b) the next
Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number
specified in this Section on a day that is not a Trading Day or later than 5:00 p.m., Boston time, on any Trading Day, (c) the
Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with next day delivery
specified, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and
communications shall be as follows:

 

	If to the Company:	Corindus Vascular Robotics, Inc.
	 	309 Waverley Oaks Road, Suite 105
	 	Waltham, MA 02452
	 	Telephone No.: (508) 653-3335
	 	Facsimile No.: (508) 232-6000
	 	Attention: Chief Executive Officer
	 	 
	With a copy to:	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	 	One Financial Center
	 	Boston, Massachusetts 02111
	 	Telephone No.: (617) 348-1799
	 	Facsimile No.: (617) 542-2241
	 	Attention: William C. Hicks
	 	Marc D. Mantell

 

    27 

     

    

 

	If to a Purchaser:	To the address set forth under such Purchaser’s name on its signature page hereto.

 

or such other address as may be designated in writing
hereafter, in the same manner, by such Person.

 

6.4       Amendments;
Waivers; No Additional Consideration. No provision of this Agreement may be waived or amended except in a written instrument
signed, in the case of an amendment, by the Company and the Purchasers holding or having the right to acquire at least a majority
of the Shares to be purchased at the Closing or then outstanding or, in the case of a waiver, by the party against whom enforcement
of any such waiver is sought; provided, however, that any such amendment that affects a Purchaser in a manner differently than
all other Purchasers shall not be effective until such amendment is signed by such Purchaser; and provided, further, that any waivers
or amendments to Sections 2.2(c), 4.7, 4.9, and 5.2 shall require the prior written consent of BSC; provided, further, that the
Company may amend Exhibit A (without the consent of the Purchasers holding or having the right to acquire at least
a majority of the Shares to be purchased at the Closing or then outstanding) solely for the purposes of adding additional Purchasers
prior to the Closing Date. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall
be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver
of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right
hereunder in any manner impair the exercise of any such right. 

 

6.5       Construction.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be construed as
if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue
of the authorship of any provisions of this Agreement or any of the Transaction Documents.

 

6.6       Successors
and Assigns. The provisions of this Agreement shall inure to the benefit of and be binding upon the parties and their successors
and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the Company without the prior
written consent of the Purchasers (other than by merger or consolidation or to an entity which acquires the Company, including
by way of acquiring all or substantially all of the Company’s assets). Any Purchaser may assign its rights hereunder in whole
or in part to any Person to whom such Purchaser assigns or transfers any Securities in compliance with the Transaction Documents
and applicable law, provided such transferee shall agree in writing to be bound, with respect to the transferred Securities, by
the terms and conditions of this Agreement that apply to the Purchasers.

 

6.7       No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

    28 

     

    

 

6.8         Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of
conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its
respective Affiliates, employees or agents) shall be commenced exclusively in the Boston Courts. Each party hereto hereby irrevocably
submits to the exclusive jurisdiction of the Boston Courts for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject
to the jurisdiction of any such Boston Court, or that such Proceeding has been commenced in an improper or inconvenient forum.
Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the
address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner
permitted by law. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL
RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

6.9         Survival.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities. Covenants to
be performed after the Closing shall survive until performed or observed in accordance with their terms.

 

6.10       Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation
of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.

 

6.11       Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor and achieves that same or substantially
the same effect or result, and upon so agreeing, shall incorporate such substitute provision in this Agreement.

 

6.12       Replacement
of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company and the Transfer
Agent of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that
fact and an agreement to indemnify and hold harmless the Company and the Transfer Agent for any losses in connection therewith
or, if required by the Transfer Agent, a bond in such form and amount as is required by the Transfer Agent. The applicants for
a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance
of such replacement Securities. If a replacement certificate or instrument evidencing any Securities is requested due to a mutilation
thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent to any issuance
of a replacement.

 

    29 

     

    

 

6.13       Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the
foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection
with any action for a temporary restraining order) the defense that a remedy at law would be adequate.

 

6.14       Payment
Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

6.15       Adjustments
in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares of Common
Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares
of Common Stock), combination or other similar recapitalization or event occurring after the date hereof, each reference in any
Transaction Document to a number of shares or a price per share shall be deemed to be amended to appropriately account for such
event.

 

6.16       Waiver
of Conflicts. Each Purchaser acknowledges that: (a) it has read this Agreement; (b) it has been represented in the preparation,
negotiation and execution of this Agreement by legal counsel of its own choice or has voluntarily declined to seek such counsel;
and (c) it understands the terms and consequences of this Agreement and is fully aware of the legal and binding effect of this
Agreement. Each Purchaser understands that the Company has been represented in the preparation, negotiation and execution of this
Agreement by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Company Counsel, and that Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C. has not represented any Purchaser or any stockholder, director or employee of the Company in the preparation, negotiation
and execution of this Agreement. Each Purchaser acknowledges that Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. may have
in the past represented and may now or may in the future represent one or more Purchasers or their Affiliates in matters unrelated
to the transactions contemplated by this Agreement, including the representation of such Purchasers or their Affiliates in matters
of a nature similar to those contemplated by this Agreement. The Company and each Purchaser hereby acknowledge that they have has
had an opportunity to ask for and have obtained information relevant to such representation, including disclosure of the reasonably
foreseeable adverse consequences of such representation, and hereby waives any conflict arising out of such representation with
respect to the matters contemplated by this Agreement.

 

    30 

     

    

 

6.17       Termination.
This Agreement may be terminated and the sale and purchase of the Shares abandoned at any time prior to the Closing by either the
Company or any Purchaser (with respect to itself only) upon written notice to the other, if the Closing has not been consummated
on or prior to 5:00 p.m., Boston time, on the Outside Date; provided, however, that the right to terminate this Agreement
under this Section 6.17 shall not be available to any Person whose failure to comply with its obligations under this Agreement
has been the primary cause of or resulted in the failure of the Closing to occur on or before such time. Nothing in this Section
6.17 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement
or the other Transaction Documents or to impair the right of any party to compel specific performance by any other party of its
obligations under this Agreement or the other Transaction Documents. Upon a termination in accordance with this Section 6.17, the
Company and the Purchaser shall not have any further obligation or liability (including arising from such termination) to the other.
The Company and Purchasers may extend the term of this Agreement in accordance with the amendment provisions of Section 6.4 herein.

 

[Remainder of Page Intentionally Left Blank;
Signature Page Follows]

 

    31 

     

    

 

In
Witness Whereof, the parties hereto have caused this Securities
Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

	 	 	 
	 	COMPANY:
	 	 	 
	 	CORINDUS
    VASCULAR ROBOTICS, INC.
	 	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	[Signature
    Pages for Purchasers Follow]

 

[Signature Page to Securities Purchase Agreement]

 

     

     

    

 

	 	PURCHASER:	 
	 	 	 	 
	 	[_________________________]	 
	 	 	 	 
	 	By:		 
	 	 	Name:	 
	 	 	Title:	 

 

	 	Aggregate Purchase Price (Subscription Amount):	 
	 	 	 	 
	 	$		 
	 	 	 
	 	Number of Shares of Common Stock to be Acquired:	 
	 	 	 	 
	 	 	 	 
	 	Address for Notice/Residency of Purchaser:	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

 

	 	Telephone No.:	 	 	 	 
	 	 	 	 	 	 
	 	Facsimile No.:	 	 	 
	 	 	 	 	 
	 	 	 	 	 	 	 
	 	E-mail Address:	 	 
	 	 	 	 
	 	Attention:	 	 	 	 	 

 

Delivery Instructions:

(if different than above)

 

	c/o	 	 	 	 	 
	 	 	 	 	 
	Street:	 	 	 	 
	 	 
	City/State/Zip:	 
	 	 	 	 
	Attention:	 	 	 
	 	 
	Telephone No.:	 

 

[Signature Page to
Securities Purchase Agreement]

 

     

     

    

 

EXHIBITS:

 

	A:	Schedule of Purchasers

	B	Form of Registration Rights Agreement

	C-1:	Accredited Investor Questionnaire

	C-2:	Stock Certificate Questionnaire

	D:	Form of Opinion of Company Counsel

	E:	Irrevocable Transfer Agent Instructions

	F:	Form of Secretary’s Certificate

	G:	Form of Compliance Certificate

 

     

     

    

 

Exhibit A

 

Schedule of Purchasers

 

	Purchaser	Subscription Amount
	 	 
	 	 
	 	 
	 	 
	 	 

 

     

     

    

 

Exhibit B

 

REGISTRATION
RIGHTS AGREEMENT

 

This
Registration Rights Agreement (this “Agreement”)
is dated as of [ ● ], 2017, by and among Corindus Vascular Robotics, Inc., a Delaware corporation (the “Company”),
and the several signatories hereto.

 

Recitals

 

This
Agreement is made pursuant to the Securities Purchase Agreement (the “Purchase Agreement”), dated as
of the date hereof between the Company and each purchaser signatory thereto (each a “Purchaser” and
collectively, the “Purchasers”).

 

Now,
Therefore, in consideration of the mutual
covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby
acknowledged, the Company and each of the Holders hereby agree as follows:

 

1.             Definitions.
Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given
such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

 

“Advice”
has the meaning set forth in Section 6(d).

 

“Affiliate”
has the meaning set forth in the Purchase Agreement.

 

“Agreement”
has the meaning set forth in the preamble.

 

“Business
Day” has the meaning set forth in the Purchase Agreement.

 

“Closing
Date” has the meaning set forth in the Purchase Agreement.

 

“Commission”
has the meaning set forth in the Purchase Agreement.

 

“Common
Stock” has the meaning set forth in the Purchase Agreement.

 

“Company”
has the meaning set forth in the preamble.

 

“Effective
Date” means the date that the Registration Statement filed pursuant to Section 2(a) is first declared effective
by the Commission.

 

“Effectiveness
Deadline” means, with respect to the Initial Registration Statement or the New Registration Statement, the 90th
calendar day following the Closing Date (or, in the event the Commission reviews and has written comments to the Initial
Registration Statement or the New Registration Statement, the 120th calendar day following the Closing Date); provided,
however, that if the Effectiveness Deadline falls on a Saturday, Sunday or other day that the Commission is closed for business,
the Effectiveness Deadline shall be extended to the next Business Day on which the Commission is open for business.

 

“Effectiveness
Period” has the meaning set forth in Section 2(b).

 

“Event”
has the meaning set forth in Section 2(c).

 

     

     

    

 

“Event
Date” has the meaning set forth in Section 2(c).

 

“Exchange
Act” has the meaning set forth in the Purchase Agreement.

 

“Filing
Deadline” means, with respect to the Initial Registration Statement required to be filed pursuant to Section 2(a),
the 45th calendar day following the Closing Date; provided, however, that if the Filing Deadline falls on a
Saturday, Sunday or other day that the Commission is closed for business, the Filing Deadline shall be extended to the next business
day on which the Commission is open for business.

 

“Holder”
or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.

 

“Indemnified
Party” has the meaning set forth in Section 5(c).

 

“Indemnifying
Party” has the meaning set forth in Section 5(c).

 

“Initial
Registration Statement” means the initial Registration Statement filed pursuant to Section 2(a) of this Agreement.

 

“Inspector”
or “Inspectors” has the meaning set forth in Section 3(k).

 

“Liquidated
Damages” has the meaning set forth in Section 2(c).

 

“Losses”
has the meaning set forth in Section 5(a).

 

“New
Registration Statement” has the meaning set forth in Section 2(a).

 

“Person”
has the meaning set forth in the Purchase Agreement.

 

“Principal
Trading Market” has the meaning set forth in the Purchase Agreement.

 

“Prior
Registration Rights Agreement” means the Demand Registration Rights Agreement dated August 8, 2014 by and among
Your Internet Defender Inc., Koninklijke Philips N.V., HealthCor Partners Fund, L.P., HealthCor Hybrid Offshore Master Fund, L.P.,
HealthCor Partners Fund II, L.P. and 20/20 Capital III LLC.

 

“Proceeding”
has the meaning set forth in the Purchase Agreement.

 

“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated
under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering
of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to
the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by
reference in such Prospectus.

 

“Purchase
Agreement” has the meaning set forth in the Recitals.

 

“Purchaser”
or “Purchasers” has the meaning set forth in the Recitals.

 

“Records”
has the meaning set forth in Section 3(k).

 

    2 

     

    

 

“Registrable
Securities” means all of the Shares and any securities issued or issuable upon any stock split, dividend or other
distribution, recapitalization or similar event with respect to the Shares, provided, that with respect to a particular
Holder, such Holder’s Shares shall cease to be Registrable Securities upon the earliest to occur of the following: (A) a
sale pursuant to a Registration Statement or Rule 144 under the Securities Act (in which case, only such security sold by the
Holder shall cease to be a Registrable Security); (B) becoming eligible for resale by the Holder under Rule 144 without the requirement
for the Company to be in compliance with the current public information requirement thereunder and without volume or manner-of-sale
restrictions, pursuant to a written opinion letter of counsel for the Company to such effect, addressed, delivered and acceptable
to the Transfer Agent; or (C) such Registrable Securities cease to be outstanding.

 

“Registration
Statements” means any one or more registration statements of the Company filed under the Securities Act that covers
the resale of any of the Registrable Securities pursuant to the provisions of this Agreement (including, without limitation, the
Initial Registration Statement, the New Registration Statement and any Remainder Registration Statements), including (in each
case) the amendments and supplements to such Registration Statements, including pre- and post-effective amendments thereto, all
exhibits and all material incorporated by reference or deemed to be incorporated by reference in such Registration Statements.

 

“Remainder
Registration Statements” has the meaning set forth in Section 2(a).

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from
time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such
Rule.

 

“Rule
415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from
time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such
Rule.

 

“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from
time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such
Rule.

 

“SEC
Guidance” means (i) any publicly-available written or oral guidance, comments, requirements or requests of the Commission
staff, provided, that any such oral guidance, comments, requirements or requests are reduced to writing by the Commission
and (ii) the Securities Act.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Selling
Stockholder Questionnaire” means a questionnaire in the form attached as Annex B hereto, or such other form
of questionnaire as may reasonably be adopted by the Company from time to time.

 

“Shares”
means the shares of Common Stock issued or issuable to the Purchasers pursuant to the Purchase Agreement.

 

“Trading
Day” has the meaning set forth in the Purchase Agreement.

 

“Trading
Market” has the meaning set forth in the Purchase Agreement.

 

    3 

     

    

 

2.             Registration.

 

(a)          On
or prior to the Filing Deadline, the Company shall prepare and file with the Commission a Registration Statement covering the
resale of all of the Registrable Securities not already covered by an existing and effective Registration Statement for an offering
to be made on a continuous basis pursuant to Rule 415 (the “Initial Registration Statement”). The Initial
Registration Statement shall be on Form S-3 (except that if the Company is then ineligible to register for resale the Registrable
Securities on Form S-3, in which case such registration shall be on such other form available to register for resale the Registrable
Securities as a secondary offering) subject to the provisions of Section 2(e) and shall contain (except if otherwise required
pursuant to written comments received from the Commission upon a review of such Registration Statement) a “Plan of Distribution”
section substantially in the form attached hereto as Annex A (which may be modified to respond to comments, if any, provided
by the Commission).

 

(i)         Notwithstanding
the registration obligations set forth in this Section 2, in the event the Commission informs the Company that all of the
Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on
a single registration statement or that any Holder must be named as an underwriter in the Registration Statement, the Company
agrees to promptly (x) inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the
Initial Registration Statement as required by the Commission and/or (y) withdraw the Initial Registration Statement and file a
new registration statement (a “New Registration Statement”), in either case covering the maximum number
of Registrable Securities permitted to be registered by the Commission, on Form S-3 or such other form available to register for
resale the Registrable Securities as a secondary offering; provided, however, that prior to filing such amendment or New
Registration Statement, the Company shall be obligated to use its commercially reasonable efforts to advocate with the Commission
for the registration of all of the Registrable Securities in accordance with SEC Guidance, including without limitation, Compliance
and Disclosure Interpretation 612.09, in each case without naming any Holder as an underwriter in the Registration Statement.
Each Purchaser shall have the right to comment or have their counsel comment on any written
submission made to the staff of Commission (the “Staff”) with respect to any disclosure specifically
relating to such Purchaser. No such written submission shall be made to the Staff containing disclosure specifically relating
to such Purchaser to which such Purchaser’s counsel reasonably objects.

 

(ii)        Notwithstanding
any other provision of this Agreement and subject to the payment of liquidated damages in Section 2(c), if any SEC Guidance sets
forth a limitation of the number of Registrable Securities permitted to be registered on a particular Registration Statement as
a secondary offering without naming any Holder as an underwriter (and notwithstanding that the Company used commercially reasonable
efforts to advocate with the Commission for the registration of all or a greater number of Registrable Securities), unless otherwise
directed in writing by a Holder as to its Registrable Securities, the Registrable Securities to be registered on such Registration
Statement will be reduced (applied, in the case that some Shares may be registered, to the Holders on a pro rata basis based on
the total number of unregistered Shares held by such Holders), subject to a determination by the Commission that certain Holders
must be reduced first based on the number of Registrable Securities held by such Holders. Any reduction of Registrable Securities
pursuant to this Section 2(a)(ii) shall occur only after all securities that are not Registrable Securities, if any, are first
removed from such Registration Statement. In the event the Company amends the Initial Registration Statement or files a New Registration
Statement, as the case may be, under clauses (x) or (y) above, the Company will use its commercially reasonable efforts to file
with the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company or to registrants of securities
in general, one or more registration statements on Form S-3 or such other form available to register for resale those Registrable
Securities that were not registered for resale on the Initial Registration Statement, as amended, or the New Registration Statement
(the “Remainder Registration Statements”). No Holder shall be named as an “underwriter”
in any Registration Statement without such Holder’s prior written consent.

 

    4 

     

    

 

(b)          The
Company shall use its commercially reasonable efforts to cause each Registration Statement to be declared effective by the Commission
as soon as practicable and, with respect to the Initial Registration Statement or the New Registration Statement, as applicable,
no later than the Effectiveness Deadline (including, with respect to the Initial Registration Statement or the New Registration
Statement, as applicable, filing with the Commission a request for acceleration of effectiveness in accordance with Rule 461 promulgated
under the Securities Act within five Business Days after the date that the Company is notified (orally or in writing, whichever
is earlier) by the Commission that such Registration Statement will not be “reviewed,” or not be subject to further
review and the effectiveness of such Registration Statement may be accelerated), and, subject to Section 2(e), shall use its commercially
reasonable efforts to keep each Registration Statement continuously effective under the Securities Act for so long as the securities
registered for resale thereunder retain their character as “Registrable Securities” (the “Effectiveness
Period”). The Company shall promptly notify the Holders via facsimile or electronic mail of the effectiveness of
a Registration Statement or any post-effective amendment thereto on or before the first Trading Day after the date that the Company
telephonically confirms effectiveness with the Commission. The Company shall, by 9:30 a.m. Boston time on the first Trading Day
after the Effective Date, file a final Prospectus with the Commission, as required by Rule 424(b).

 

(c)          If:
(i) the Initial Registration Statement is not filed with the Commission on or prior to the Filing Deadline, (ii) the Initial Registration
Statement or the New Registration Statement, as applicable, is not declared effective by the Commission (or otherwise does not
become effective) for any reason on or prior to the Effectiveness Deadline or (iii) after its Effective Date and except for the
reasons as set forth in Section 3(h), (A) such Registration Statement ceases for any reason (including, without limitation, by
reason of a stop order or the Company’s failure to update the Registration Statement), to remain continuously effective
as to all Registrable Securities included in such Registration Statement or (B) the Holders are not permitted to utilize the Prospectus
therein to resell such Registrable Securities for any reason (other than due to a change in the “Plan of Distribution”
or the inaccuracy of any information regarding the Holders), in each case, for more than an aggregate of 45 calendar days (which
need not be consecutive days) during any 12-month period (other than as a result of a material breach of this Agreement by a Holder
or a Holder’s failure to return a Selling Stockholder Questionnaire within the time period provided by Section 2(d) hereof)
(any such failure or breach in clauses (i) through (iii) above being referred to as an “Event,” and,
for purposes of clauses (i) or (ii), the date on which such Event occurs, or for purposes of clause (iii), the date on which such
45 calendar day period is exceeded, being referred to as an “Event Date”), then in addition to any other
rights the Holders may have hereunder or under applicable law: (x) within five Business Days after an Event Date relating to a
failure in clause (i) only, the Company shall pay to each Holder an amount in cash, as liquidated damages and not as a penalty,
equal to 1.0% of the aggregate purchase price paid by such Holder pursuant to the Purchase Agreement for any Registrable Securities
held by such Holder on such Event Date; and (y) on each 30-day anniversary (or pro rata portion thereof) following any Event Date
(including, for the avoidance of doubt, a failure in clause (i), in which case each 30-day anniversary shall be measured commencing
on the 31st day following such Event Date) until the earlier of (1) the applicable Event is cured or (2) the Registrable
Securities are eligible for resale pursuant to Rule 144 without manner of sale or volume restrictions, the Company shall pay to
each Holder an amount in cash, as liquidated damages and not as a penalty, equal to 1.0% of the aggregate purchase price paid
by such Holder pursuant to the Purchase Agreement for any unregistered Registrable Securities then held by such Holder. The amounts
payable pursuant to the foregoing clauses (x) and (y) are referred to collectively as “Liquidated Damages.”
The parties agree that (1) notwithstanding anything to the contrary herein or in the Purchase Agreement, no Liquidated Damages
shall be payable with respect to any period after the expiration of the Effectiveness Period and in no event shall the aggregate
amount of Liquidated Damages payable to a Holder exceed, in the aggregate, 6.0% of the aggregate purchase price paid by such Holder
pursuant to the Purchase Agreement and (2) in no event shall the Company be liable in any 30-day period for Liquidated Damages
under this Agreement in excess of 1.0% of the aggregate purchase price paid by the Holders pursuant to the Purchase Agreement.
If the Company fails to pay any Liquidated Damages pursuant to this Section 2(c) in full within 30 Business Days after the date
payable, the Company will pay interest thereon at a rate of 1.0% per month (or such lesser maximum amount that is permitted to
be paid by applicable law) to the Holder, accruing daily from the date such Liquidated Damages are due until such amounts, plus
all such interest thereon, are paid in full. Unless otherwise specified in Section 2(c), the Liquidated Damages pursuant to the
terms hereof shall apply on a daily pro-rata basis for any portion of a month prior to the cure of an Event, except in the case
of the first Event Date. Notwithstanding the foregoing, nothing shall preclude any Holder from pursuing or obtaining any available
remedies at law, specific performance or other equitable relief with respect to this Section 2(c) in accordance with applicable
law. The Company shall not be liable for Liquidated Damages under this Agreement as to any Registrable Securities which may then
be resold under Rule 144 or which are not permitted by the Commission to be included in a Registration Statement due solely to
SEC Guidance from the time that it is determined that such Registrable Securities are not permitted to be registered until such
time as the provisions of this Agreement as to the Remainder Registration Statements required to be filed hereunder are triggered,
in which case the provisions of this Section 2(c) shall once again apply, if applicable. In such case, the Liquidated Damages
shall be calculated to only apply to the percentage of Registrable Securities which are permitted in accordance with SEC Guidance
to be included in such Registration Statement. The Effectiveness Deadline for a Registration Statement shall be extended without
default or Liquidated Damages hereunder in the event that the Company’s failure to obtain the effectiveness of the Registration
Statement on a timely basis results from the failure of a Holder to timely provide the Company with information requested by the
Company and necessary to complete the Registration Statement in accordance with the requirements of the Securities Act (in which
the Effectiveness Deadline would be extended with respect to Registrable Securities held by such Holder).

 

    5 

     

    

 

(d)          Each
Holder agrees to furnish to the Company a completed Selling Stockholder Questionnaire not more than ten Trading Days following
the date of this Agreement. At least five Trading Days prior to the first anticipated filing date of a Registration Statement
for any registration under this Agreement, the Company will notify each Holder of the information the Company requires from that
Holder other than the information contained in the Selling Stockholder Questionnaire, if any, which shall be completed and delivered
to the Company promptly upon request and, in any event, within two Trading Days prior to the applicable anticipated filing date.
Each Holder further agrees that it shall not be entitled to be named as a selling security holder in the Registration Statement
or use the Prospectus for offers and resales of Registrable Securities at any time, unless such Holder has returned to the Company
a completed and signed Selling Stockholder Questionnaire and a response to any reasonable requests for further information as
described in the previous sentence. If a Holder of Registrable Securities returns a Selling Stockholder Questionnaire or a request
for further information, in either case, after its respective deadline, the Company shall use its commercially reasonable efforts
to take such actions as are required to name such Holder as a selling security holder in the Registration Statement or any pre-effective
or post-effective amendment thereto and to include (to the extent not theretofore included) in the Registration Statement the
Registrable Securities identified in such late Selling Stockholder Questionnaire or request for further information. Each Holder
acknowledges and agrees that the information in the Selling Stockholder Questionnaire or request for further information as described
in this Section 2(d) will be used by the Company in the preparation of the Registration Statement and hereby consents to the inclusion
of such information in the Registration Statement.

 

(e)          In
the event that Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall
(i) register the resale of the Registrable Securities on Form S-1 and (ii) undertake to register the Registrable Securities on
Form S-3 promptly after such form is available, provided that the Company shall maintain the effectiveness of the Registration
Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been
declared effective by the Commission.

 

    6 

     

    

 

3.             Registration
Procedures.

 

In
connection with the Company’s registration obligations hereunder, the Company shall:

 

(a)          Not
less than five Trading Days prior to the filing of each Registration Statement and not less than three Trading Days prior to the
filing of any related Prospectus or any amendment or supplement thereto (except for Annual Reports on Form 10-K, and Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K and any similar or successor reports), (i) furnish to the Holder copies of
such Registration Statement, Prospectus or amendment or supplement thereto, substantially in the form as proposed to be filed,
which documents will be subject to the review of such Holder (it being acknowledged and agreed that if a Holder does not object
to or comment on the aforementioned documents within such five Trading Day or three Trading Day period, as the case may be, then
the Holder shall be deemed to have consented to and approved the use of such documents) and (ii) use commercially reasonable efforts
to cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall
be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct such review. The Company shall not file
any Registration Statement or Prospectus or any amendment or supplement thereto in a form to which a Holder reasonably objects
in good faith, provided that, the Company is notified of such objection in writing within the five Trading Day or three
Trading Day period described above, as applicable, and provided further, that no such delay in filing shall result in any
Liquidated Damages under Section 2(c).

 

(b)          (i)
Subject to Section 3(h), prepare and file with the Commission such amendments (including post-effective amendments) and supplements
to each Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement
continuously effective as to the applicable Registrable Securities for its Effectiveness Period; (ii) cause the related Prospectus
to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented
or amended, to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably practicable to any comments received from
the Commission with respect to each Registration Statement or any amendment thereto and, as promptly as reasonably possible, provide
the Holders true and complete copies of all correspondence from and to the Commission relating to such Registration Statement
that pertains to the Holders as “Selling Stockholders” but not any comments that would result in the disclosure to
the Holders of material and non-public information concerning the Company; and (iv) comply with the provisions of the Securities
Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement until
such time as all of such Registrable Securities cease to be Registrable Securities or shall have been disposed of (subject to
the terms of this Agreement) in accordance with the intended methods of disposition by the Holders thereof as set forth in such
Registration Statement as so amended or in such Prospectus as so supplemented; provided, however, that in the event the
Company informs the Holders in writing that it does not satisfy the conditions specified in Rule 172 and, as a result thereof,
the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities, the Company shall
deliver to the Holders a copy of the Prospectus in electronic format and each such Holder shall be responsible for the delivery
of the Prospectus to the Persons to whom such Holder sells any of the Registrable Securities, and each Holder agrees to dispose
of Registrable Securities in compliance with the “Plan of Distribution” described in the Registration Statement and
otherwise in compliance with applicable federal and state securities laws. In the case of amendments and supplements to a Registration
Statement which are required to be filed pursuant to this Agreement (including pursuant to this Section 3(b)) by reason of the
Company filing a report on Form 10-K, Form 10-Q or Form 8-K or any analogous report under the Exchange Act, the Company shall
have incorporated such report by reference into such Registration Statement, if applicable, or shall file such amendments or supplements
with the Commission on the same day on which the Exchange Act report which created the requirement for the Company to amend or
supplement such Registration Statement was filed.

 

    7 

     

    

 

(c)          Notify
the Holders (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied by an instruction to suspend the
use of the Prospectus until the requisite changes have been made) as promptly as reasonably practicable via facsimile or electronic
mail (and, in the case of (i)(A) below, not less than three Trading Days prior to such filing) and no later than two Trading Days
following the day: (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement
is proposed to be filed; (B) when the Commission notifies the Company whether there will be a “review” of such Registration
Statement and whenever the Commission comments in writing on any Registration Statement (in which case the Company shall provide
to each of the Holders true and complete copies of all comments that pertain to the Holders as a “Selling Stockholder”
or to the “Plan of Distribution” and all written responses thereto, but not information that the Company believes
would constitute material and non-public information); and (C) with respect to each Registration Statement or any post-effective
amendment thereto, when the same has become effective; (ii) of any request by the Commission or any other Federal or state governmental
authority for amendments or supplements to a Registration Statement or Prospectus or for additional information that pertains
to the Holders as “Selling Stockholders” or the “Plan of Distribution”; (iii) of the issuance by the Commission
or any other Federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement
covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose; (iv) of the receipt by
the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of
the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose and
(v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement
ineligible for inclusion therein or any statement made in such Registration Statement or Prospectus or any document incorporated
or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to such Registration
Statement, Prospectus or other documents so that, in the case of such Registration Statement or the Prospectus, as the case may
be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein (in the case of any Prospectus, form of prospectus or supplement thereto, in light
of the circumstances under which they were made), not misleading; and (vi) of the occurrence or existence of, or in anticipation
of, any acquisition, financing activity, regulatory developments or other material transaction involving the Company, or any other
event or condition of similar significance to the Company, for which allowing the continued availability of a Registration Statement
or Prospectus would be, in the good faith determination of the Board of Directors, materially detrimental to the Company, provided
that, any and all such information shall remain confidential to each Holder until such information otherwise becomes public,
unless disclosure by a Holder is required by law; and provided, further, that notwithstanding each Holder’s
agreement to keep such information confidential, each such Holder makes no acknowledgement that any such information is material,
non-public information.

 

(d)          Use
commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order suspending the
effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any
of the Registrable Securities for sale in any jurisdiction, as soon as practicable.

 

(e)          If
requested by a Holder, furnish to such Holder, without charge, at least one conformed copy of each Registration Statement and
each amendment thereto and all exhibits to the extent requested by such Person (including those previously furnished or incorporated
by reference) promptly after the filing of such documents with the Commission; provided, that the Company shall have no
obligation to provide any document pursuant to this clause that is available on the Commission’s EDGAR system.

 

    8 

     

    

 

(f)          Prior
to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate
with the selling Holders in connection with the registration or qualification (or exemption from the registration or qualification)
of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within
the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom)
effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition
in such jurisdictions of the Registrable Securities covered by each Registration Statement; provided, that the Company
shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, would subject
the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service
of process in any such jurisdiction.

 

(g)          If
requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates or book-entry
statements representing Registrable Securities to be delivered to a transferee pursuant to the Registration Statement, which certificates
or book entry statements shall be free, to the extent permitted by the Purchase Agreement, and under law, of all restrictive legends,
and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holders may reasonably
request.

 

(h)          Following
the occurrence of any event contemplated by Section 3(c), as promptly as reasonably practicable (taking into account the Company’s
good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event),
prepare a supplement or amendment, including a post-effective amendment, to the affected Registration Statements or a supplement
to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required
document so that, as thereafter delivered, no Registration Statement nor any Prospectus will contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein (in the
case of any Prospectus, form of prospectus or supplement thereto, in light of the circumstances under which they were made), not
misleading. If the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section 3(c) above to suspend
the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of
such Prospectus. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed
as promptly as is practicable. The Company shall be entitled to exercise its right under this Section 3(h) to suspend the availability
of a Registration Statement and Prospectus for a period not to exceed 45 calendar days (which need not be consecutive days) in
any 12-month period without incurring liability for Liquidated Damages otherwise required pursuant to Section 2(c).

 

(i)          The
Company may require each selling Holder to furnish to the Company a certified statement as to (i) the number of shares of Common
Stock beneficially owned by such Holder and any Affiliate thereof, (ii) any Financial Industry Regulatory Authority, Inc. (“FINRA”)
affiliations, (iii) any natural persons who have the power to vote or dispose of the common stock and (iv) any other information
as may be requested by the Commission, FINRA or any state securities commission. During any periods that the Company is unable
to meet its obligations hereunder with respect to the registration of Registrable Securities because any Holder fails to furnish
such information within three Trading Days of the Company’s request, any Liquidated Damages that are accruing at such time
as to such Holder only shall be tolled and any Event that may otherwise occur solely because of such delay shall be suspended
as to such Holder only, until such information is delivered to the Company; provided, however, if the failure of
the Holder to furnish the required information results the occurrence of an Event under 2(c), any Liquidated Damages that are
accruing at such time shall be tolled and any such Event that occurs as a result thereof shall be suspended until such time as
the Holder furnishes such information.

 

    9 

     

    

 

(j)          The
Company shall cooperate with any registered broker through which a Holder proposes to resell its Registrable Securities in effecting
a filing with FINRA pursuant to FINRA Rule 5110 as reasonably requested by any such Holder, and the Company shall pay the filing
fee required for the first such filing within five Business Days of the request therefor.

 

(k)          At
the request of any managing underwriter, make available at reasonable times for inspection by such managing underwriter and such
managing underwriter’s legal counsel and any attorney, accountant or other agent retained by such managing underwriter (each,
an “Inspector” and collectively, the “Inspectors”), all financial and other
records, pertinent corporate documents and properties of the Company and its subsidiaries (collectively, the “Records”)
as shall be reasonably necessary to enable them to exercise their due diligence responsibility, and cause the Company’s
and its subsidiaries’ officers, directors and employees, and the independent public accountants of the Company, to supply
all information reasonably requested by any such Inspector in connection with such Registration Statement. Notwithstanding the
foregoing, Records and other information that the Company determines, in good faith, to be confidential and which it notifies
the Inspectors are confidential shall not be disclosed by the Inspectors or used for any purpose other than as necessary or appropriate
for the purpose of such inspection (and the Inspectors shall confirm their agreement in writing in advance to the Company if the
Company shall so request) unless (i) the disclosure of such Records is necessary, in the Company’s judgment, to avoid or
correct a misstatement or omission in the Registration Statement, (ii) the release of such Records is ordered pursuant to a subpoena
or other order from a court of competent jurisdiction after exhaustion of all appeals therefrom or (iii) the information in such
Records was known to the Inspectors on a non-confidential basis prior to its disclosure by the Company or has been made generally
available to the public.

 

(l)          If
such sale is pursuant to an underwritten offering, (i) obtain “comfort” letters dated the pricing and closing dates
of such offering under the underwriting agreement from the Company’s independent public accountants in customary form and
covering such matters of the type customarily covered by “comfort” letters as the managing underwriter reasonably
requests; (ii) enter into a customary underwriting agreement with the underwriter containing customary representations and warranties,
covenants and legal opinions addressed to the underwriters; (iii) take other such actions as reasonably required in order to expedite
or facilitate the disposition of such Registrable Securities, including causing its officers to participate in “road shows”
and other information meetings organized by the underwriters, if applicable, of reasonable and customary duration and frequency
(but not to exceed five days in each instance); or (iv) deliver such documents and certificates as may be reasonably requested
and as are customarily delivered in similar offerings.

 

(m)          Cause
all such Registrable Securities to be listed on each securities exchange on which similar securities issued by the Company are
then listed.

 

    10 

     

    

 

4.             Registration
Expenses. All fees and expenses incident to the Company’s performance of or compliance with its obligations under this
Agreement (excluding any underwriting discounts and selling commissions and all legal fees and expenses of legal counsel for any
Holder) shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement.
The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing
fees (including, without limitation, fees and expenses (A) with respect to filings required to be made with any Trading Market
on which the Common Stock is then listed for trading, (B) with respect to compliance with applicable state securities or Blue
Sky laws (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications
or exemptions of the Registrable Securities and determination of the eligibility of the Registrable Securities for investment
under the laws of such jurisdictions as requested by the Holders, but not including any jurisdictions outside the United States)
and (C) if not previously paid by the Company pursuant to Section 3(j) hereof, with respect to any filing that may be required
to be made by any broker through which a Holder intends to make sales of Registrable Securities with FINRA pursuant to FINRA Rule
5110), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities and
of printing prospectuses if the printing of prospectuses is reasonably requested by the Holders of a majority of the Registrable
Securities included in the Registration Statement), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements
of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and
expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by
this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the
consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its
officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred
in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall
the Company be responsible for any underwriting, broker or similar fees or commissions of any Holder or any legal fees or other
costs of the Holders.

 

5.             Indemnification.

 

(a)          Indemnification
by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder,
the officers, directors, agents, partners, members, managers, stockholders, Affiliates and employees of each of them, each Person
who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the
officers, directors, partners, members, managers, stockholders, agents and employees of each such controlling Person, to the fullest
extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, amounts paid in settlement
in accordance with Section 5(c) hereof, costs (including, without limitation, reasonable costs of preparation and investigation
and reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred, that arise
out of or are based upon (i) any untrue or alleged untrue statement of a material fact contained in any Registration Statement,
any Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto
for this purpose), or arising out of or relating to any omission or alleged omission to state a material fact required to be stated
therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances
under which they were made) not misleading or (ii) any violation or alleged violation by the Company of the Securities Act, the
Exchange Act or any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable
Securities pursuant to the Registration Statement, except to the extent, but only to the extent that (A) such untrue statements,
alleged untrue statements, omissions or alleged omissions are based solely upon information regarding such Holder furnished in
writing to the Company by such Holder, or to the extent that such information relates to such Holder or such Holder’s proposed
method of distribution of Registrable Securities and was reviewed and approved in writing by such Holder expressly for use in
the Registration Statement, such Prospectus or in any amendment or supplement thereto (it being understood that each Holder has
approved Annex A hereto for this purpose); provided, that such untrue statement or alleged untrue statement or omission
or alleged omission had not been corrected in such Prospectus or in any amendment or supplement thereto prior to, or concurrently
with, the sale of Registrable Securities to the person asserting the applicable indemnification claim, or (B) in the case of an
occurrence of an event of the type specified in Section 3(c)(iii)-(vi), related to the use by a Holder of an outdated or defective
Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior to the
receipt by such Holder of the Advice contemplated and defined in Section 6(d) below, following the receipt of the Advice the misstatement
or omission giving rise to such Loss would have been corrected, or (C) any such Losses arise out of the Purchaser’s (or
any other indemnified Person’s) failure to send or give a copy of the Prospectus or supplement (as then amended or supplemented),
if required pursuant to Rule 172 under the Securities Act (or any successor rule), to the Persons asserting an untrue statement
or alleged untrue statement or alleged untrue statement or omission or alleged omission at or prior to the written confirmation
of the sale of Registrable Securities to such Person if such statement or omission was corrected in such Prospectus or supplement.
The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection
with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force
and effect regardless of any investigation made by or on behalf of an Indemnified Party (as defined in Section 5(c)) and shall
survive the transfer of the Registrable Securities by the Holders.

 

    11 

     

    

 

(b)          Indemnification
by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers,
agents, stockholders, Affiliates and employees, each Person who controls the Company (within the meaning of Section 15 of the
Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons,
to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising out of or are based solely
upon any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in
any amendment or supplement thereto, or arising out of or relating to any omission or alleged omission of a material fact required
to be stated therein or necessary to make the statements therein (in the case of any Prospectus, or supplement thereto, in light
of the circumstances under which they were made) not misleading (i) to the extent, but only to the extent, that such untrue statements
or omissions are based upon information regarding such Holder furnished in writing to the Company by such Holder expressly for
use therein and such untrue statement or alleged untrue statement or omission or alleged omission had not been corrected in such
Prospectus or in any amendment or supplement thereto prior to, or concurrently with, the sale of Registrable Securities to the
person asserting the applicable indemnification claim, or (ii) to the extent that such information relates to such Holder or such
Holder’s proposed method of distribution of Registrable Securities and was reviewed and approved in writing by such Holder
expressly for use in a Registration Statement (it being understood that the Holder has approved Annex A hereto for this
purpose), such Prospectus or in any amendment or supplement thereto or (iii) in the case of an occurrence of an event of the type
specified in Section 3(c)(iii)-(vi), to the extent, but only to the extent, related to the use by such Holder of an outdated or
defective Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior
to the receipt by such Holder of the Advice contemplated in Section 6(d). In no event shall the liability of any selling Holder
hereunder (together with any liability under Section 5(d)) be greater in amount than the dollar amount of the net proceeds received
by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.

 

(c)          Conduct
of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder
(an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity
is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to
assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment
of all reasonable fees and expenses incurred in connection with defense thereof, provided, that the failure of any Indemnified
Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement,
except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination
is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying
Party.

 

    12 

     

    

 

An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof,
but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (i) the Indemnifying
Party has agreed in writing to pay such fees and expenses; (ii) the Indemnifying Party shall have failed promptly to assume the
defense of such Proceeding or the Indemnifying Party does not, upon assuming the defense of such Proceeding, conduct the defense
of such claim actively and diligently; (iii) the named parties to any such Proceeding (including any impleaded parties) include
both such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict
of interest exists if the same counsel were to represent such Indemnified Party and the Indemnifying Party; (iv) the claim is
based upon any Proceeding, indictment, allegation or investigation of a criminal nature; or (v) the claim seeks an injunction
or non-monetary or equitable relief against the Indemnified Party, other than any such claim that is incidental to the primary
claim or claims and not material (in the case of clauses (ii)-(v), if such Indemnified Party notifies the Indemnifying Party in
writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have
the right to assume the defense thereof and such counsel shall be at the expense of the Indemnifying Party); provided,
that the Indemnifying Party shall not be liable for the fees and expenses of more than one separate firm of attorneys at any time
for all Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without
its prior written consent, which consent shall not be unreasonably withheld, delayed or conditioned. No Indemnifying Party shall,
without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which
any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all
liability on claims that are the subject matter of such Proceeding and such settlement does not require any Indemnified Party
to perform any covenant or refrain from engaging in any activity or include any non-monetary limitation on the actions of any
Indemnified Party or any of its affiliates or any admission of fault, violation, culpability, malfeasance or nonfeasance by, or
on behalf of, or liability on behalf of, any such Indemnified Party.

 

Subject
to the terms of this Agreement, all fees and expenses of the Indemnified Party (including reasonable fees and expenses to the
extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this
Section 5) shall be paid to the Indemnified Party, as incurred, within 20 Trading Days of written notice thereof to the Indemnifying
Party; provided, that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees
and expenses applicable to such actions for which such Indemnified Party is finally judicially determined to not be entitled to
indemnification hereunder. The failure to deliver written notice to the Indemnifying Party within a reasonable time of the commencement
of any such action shall not relieve such Indemnifying Party of any liability to the Indemnified Party under this Section 5, except
to the extent that the Indemnifying Party is materially and adversely prejudiced in its ability to defend such action.

 

(d)          Contribution.
If a claim for indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified
Party harmless for any Losses, then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute
to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect
the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that
resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party
and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue
or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by,
or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge,
access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by
a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable
attorneys’ or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent such
party would have been indemnified for such fees or expenses if the indemnification provided for in this Section 5 was available
to such party in accordance with its terms.

 

    13 

     

    

 

The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by
pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred
to in the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), (A) no Holder shall be required
to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by such Holder
from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such Holder has otherwise
been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission, including pursuant
to Section 5(b) above, and (B) no contribution will be made under circumstances where the maker of such contribution would not
have been required to indemnify the Indemnified Party under the fault standards set forth in this Section 5. No person guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution
from any Person who was not guilty of such fraudulent misrepresentation.

 

6.             Piggyback
Registrations

 

(a)          If,
at any time when there are Registrable Securities then outstanding aside from the period beginning on the date when the Company
files the Initial Registration Statement with the Commission and ending on the date when the Commission declares the Initial Registration
Statement effective, there is not an effective Registration Statement covering all of the Registrable Securities and the Company
shall determine to prepare and file with the Commission a registration statement relating to an offering for its own account or
the account of others under the Securities Act of any of its equity securities (other than a registration statement relating to
a rights offering, or on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating
to equity securities to be issued solely in connection with any acquisition of or merger with any entity or business or equity
securities issuable in connection with the Company’s equity incentive or other employee benefit plans), and even if there
is such an effective Registration Statement covering all of the Registrable Securities, in the event that such offering for its
own account or the account of others is to be underwritten, then the Company shall deliver to each Holder a written notice of
such determination, and if, within ten (10) days after the date of the delivery of such notice, any such Holder shall so request
in writing, the Company shall use its commercially reasonable efforts to include in such registration statement all or any part
of any Registrable Securities such Holder requests to be registered. The Company shall have the right to postpone, terminate or
withdraw any registration initiated by it under this Section 6(a) prior to the effectiveness of such registration whether or not
any Holder has elected to include securities in such registration. 

 

    14 

     

    

 

(b)          The
right of any Holder to registration pursuant to this Section 6 in connection with an underwritten offering shall be conditioned
upon such Holder’s participation in such underwriting and the inclusion of Registrable Securities in the underwriting to
the extent provided herein. Each Holder proposing to distribute its securities through such underwriting shall (together with
the Company and the other holders distributing their securities through such underwriting) enter into and perform such Holder’s
obligations under an underwriting agreement with the managing underwriter(s) selected for such underwriting by the Company or
other holder of securities having the right to select such managing underwriter(s) (such underwriting agreement to be in the form
negotiated by the Company). Notwithstanding any other provision of this Section 6, if the managing underwriter or underwriters
of a proposed underwritten offering with respect to which Holders of Registrable Securities have exercised their piggyback registration
rights advise the Board in writing that in its or their good faith opinion the number of Registrable Securities requested to be
included in the offering thereby and all other securities proposed to be sold in the offering exceeds the number which can be
sold in such underwritten offering without adversely affecting the success of such offering, in light of market conditions, the
Registrable Securities and such other securities to be included in such underwritten offering shall be allocated, (i) first, up
to the total number of securities that the Company has requested to be included in such registration, if such registration has
been initiated by the Company, or that any other holder of securities has requested to be included in such registration, if such
registration has been initiated by such other holder, (ii) second, and only if all the securities referred to in clause (i) have
been included, all other securities proposed to be included in such offering by Holders and other holders with registration rights
pursuant to the Prior Registration Rights Agreement (pro rata based upon the number of securities that each of them shall
have so requested to be included in such offering), and (iii) third, and only if all the securities referred to in clauses (i)
and (ii) have been included, all other securities proposed to be included in such offering by Holders and other holders with registration
rights (pro rata based upon the number of securities that each of them shall have so requested to be included in such offering)
that, in the opinion of the managing underwriter or underwriters, can be sold without having such adverse effect. If any Holder
disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company
and the managing underwriter (provided that, if the managing underwriter(s) have provided such Holder with written notice of the
date on which the applicable Registration Statement will become effective no later than five (5) Business Days prior to such effectiveness
date, such Holder’s written notice of such election must be given at least three (3) Business Days prior to effectiveness
of the applicable Registration Statement). Any securities excluded or withdrawn from such underwriting shall be withdrawn from
such registration. 

 

7.             Rule
144 Compliance. With a view to making available to the Holders the benefits of Rule 144 under the Securities Act and any other
rule or regulation of the Commission that may at any time permit a Holder to sell securities of the Company to the public without
registration, the Company shall:

 

(i)         use
commercially reasonable efforts to make and keep public information available, as those terms are understood and defined in Rule
144 under the Securities Act;

 

(ii)        use
commercially reasonable efforts to file with the Commission in a timely manner all reports and other documents required of the
Company under the Exchange Act, at any time when the Company is subject to such reporting requirements; and

 

(iii)       furnish
to any Holder, promptly upon request, a written statement by the Company as to its compliance with the reporting requirements
of Rule 144 under the Securities Act and of the Exchange Act, a copy of the most recent annual or quarterly report of the Company,
and such other reports and documents so filed or furnished by the Company with the Commission as such Holder may reasonably request
in connection with the sale of Registrable Securities without registration (in each case to the extent not readily publicly available).

 

8.             Miscellaneous.

 

(a)          Remedies.
The Company and each Holder agree that monetary damages may not provide adequate compensation for any losses incurred by reason
of a breach by it of any of the provisions of this Agreement and hereby further agrees that, subject to the limitations set forth
elsewhere in this Agreement, in the event of a breach by the Company or by a Holder of any of their obligations under this Agreement,
each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under
this Agreement, including recovery of damages, may be entitled to specific performance of its rights under this Agreement.

 

    15 

     

    

 

(b)          Compliance.
Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable
to it (unless an exemption therefrom is available) in connection with sales of Registrable Securities pursuant to the Registration
Statement, and shall sell the Registrable Securities only in accordance with a method of distribution described in the Registration
Statement

 

(c)          Discontinued
Disposition. By its acquisition of Registrable Securities, the Holder agrees that, upon receipt of a notice from the Company
of the occurrence of any event of the kind described in Section 3(c)(iii)-(vi), such Holder will forthwith discontinue disposition
of such Registrable Securities under a Registration Statement until it is advised in writing (the “Advice”)
by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company
will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable.
The Company may provide appropriate stop orders to enforce the provisions of this paragraph.

 

(d)          No
Inconsistent Agreements. The Company has not entered, as of the date hereof, nor shall the Company, on or after the date hereof,
enter into any agreement with respect to its securities, that would have the effect of impairing the rights granted to the Holders
in this Agreement or otherwise conflicts with the provisions hereof.

 

(e)          Amendments
and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or
supplemented, or waived unless the same shall be in writing and signed by the Company and Holders holding no less that a majority
of the then outstanding Registrable Securities or, if such amendment, modification or supplement shall affect a Holder in a manner
disproportionate from other Holders then the signature of such Holder shall be required, provided that any party may give
a waiver as to itself. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to
a matter that relates exclusively to the rights of Holders and that does not directly or indirectly affect the rights of other
Holders may be given by Holders of all of the Registrable Securities to which such waiver or consent relates; provided,
however, that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the
provisions of the immediately preceding sentence.

 

(f)          Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as
set forth in the Purchase Agreement.

 

(g)          Successors
and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each
of the parties and shall inure to the benefit of each Holder. Nothing in this Agreement, express or implied, is intended to confer
upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or
liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. The Company may not assign its
rights (except by merger or in connection with another entity acquiring all or substantially all of the Company’s assets)
or obligations hereunder without the prior written consent of all the Holders of the then outstanding Registrable Securities.
Each Holder may assign its respective rights hereunder in the manner and to the Persons as permitted under the Purchase Agreement
provided in each case that (i) the Holder agrees in writing with the transferee or assignee to assign such rights and related
obligations under this Agreement, and for the transferee or assignee to assume such obligations, and a copy of such agreement
is furnished to the Company within a reasonable time after such assignment, (ii) the Company is, within a reasonable time after
such transfer or assignment, furnished with written notice of the name and address of such transferee or assignee and the securities
with respect to which such registration rights are being transferred or assigned, (iii) at or before the time the Company received
the written notice contemplated by clause (ii) of this sentence, the transferee or assignee agrees in writing with the Company
to be bound by all of the provisions contained herein and (iv) the transferee is an “accredited investor,” as that
term is defined in Rule 501 of Regulation D.

 

    16 

     

    

 

(h)          Execution
and Counterparts. This Agreement may be executed in two or more counterparts, each of which when so executed shall be deemed
to be an original and, all of which taken together shall constitute one and the same Agreement and shall become effective when
counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign
the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf”
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such facsimile or “.pdf” signature were the original thereof.

 

(i)          Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined
in accordance with the provisions of the Purchase Agreement.

 

(j)          Cumulative
Remedies. Except as provided herein, the remedies provided herein are cumulative and not exclusive of any other remedies provided
by law.

 

(k)          Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain
in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their good
faith reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that
contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the
parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such
that may be hereafter declared invalid, illegal, void or unenforceable.

 

(l)          Headings.
The headings in this Agreement are for convenience only and shall not limit or otherwise affect the meaning hereof.

 

[Remainder
of Page Intentionally Left Blank; Signature Page Follows] 

 

    17 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

 

	 	CORINDUS
VASCULAR ROBOTICS, INC.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

     

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

 

	 	HOLDER:	 
	 	 
	 	AUTHORIZED SIGNATORY
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	ADDRESS FOR NOTICE

	 	 	 	 	 
	 	c/o:	 
	 	 	 
	 	Street:	 
	 	 	 
	 	City/State/Zip:	 
	 	 	 
	 	Attention:	 
	 	 	 
	 	Tel:	 
	 	 	 
	 	Fax:	 
	 	 	 
	 	Email:	 

 

     

     

    

 

Annex
A

 

PLAN
OF DISTRIBUTION

 

The
selling stockholders and any of their pledgees, donees, transferees, assignees or other successors-in-interest may, from time
to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock
on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions
may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at
varying prices determined at the time of sale, or at negotiated prices. The selling stockholders may use one or more of the following
methods when disposing of the shares or interests therein: 

 

		●	ordinary
                                         brokerage transactions and transactions in which the broker-dealer solicits purchasers;

 

		●	block
                                         trades in which the broker-dealer will attempt to sell the shares as agent but may position
                                         and resell a portion of the block as principal to facilitate the transaction;

 

		●	through
                                         brokers, dealers or underwriters that may act solely as agents;

 

		●	purchases
                                         by a broker-dealer as principal and resale by the broker-dealer for its account;

 

		●	an
                                         exchange distribution in accordance with the rules of the applicable exchange;

 

		●	privately
                                         negotiated transactions;

 

		●	through
                                         the writing or settlement of options or other hedging transactions entered into after
                                         the effective date of the registration statement of which this prospectus is a part,
                                         whether through an options exchange or otherwise;

  

		●	broker-dealers
                                         may agree with the selling stockholder to sell a specified number of such shares at a
                                         stipulated price per share;

 

		●	one
                                         or more underwritten offerings on a firm commitment or best efforts basis;

 

		●	a
combination of any such methods of disposition; and

  

		●	any
                                         other method permitted pursuant to applicable law.

 

The
selling stockholders may also sell shares under Rule 144 under the Securities Act of 1933, as amended, or Securities Act, if available,
rather than under this prospectus.

 

Broker-dealers
engaged by the selling stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser)
in amounts to be negotiated. The selling stockholders do not expect these commissions and discounts to exceed what is customary
in the types of transactions involved.

 

     

     

    

 

The
selling stockholders may from time to time pledge or grant a security interest in some or all of the shares of common stock owned
by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell
shares of common stock from time to time under this prospectus, or under a supplement or amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee,
transferee or other successors in interest as selling stockholders under this prospectus.

 

Upon
being notified in writing by a selling stockholder that any material arrangement has been entered into with a broker-dealer for
the sale of common stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase
by a broker or dealer, we will file a supplement to this prospectus, if required, pursuant to Rule 424(b) under the Securities
Act, disclosing (i) the name of such selling stockholder and of the participating broker-dealer(s), (ii) the number of shares
involved, (iii) the price at which such shares of common stock were sold, (iv) the commissions paid or discounts or concessions
allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify
the information set out or incorporated by reference in this prospectus, and (vi) other facts material to the transaction. In
addition, upon being notified in writing by the selling stockholder that a donee or pledge intends to sell more than 500 shares
of common stock, we will file a supplement to this prospectus if then required in accordance with applicable securities law.

 

The
selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees
or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

 

In
connection with the sale of the shares of common stock or interests in shares of common stock, the selling stockholders may enter
into hedging transactions after the effective date of the registration statement of which this prospectus is a part with broker-dealers
or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions
they assume. The selling stockholders may also sell shares of common stock short after the effective date of the registration
statement of which this prospectus is a part and deliver these securities to close out their short positions, or loan or pledge
the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option
or other transactions after the effective date of the registration statement of which this prospectus is a part with broker-dealers
or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

 

The
selling stockholders and any broker-dealers or agents that are involved in selling the shares may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act.

 

We
have advised the selling stockholders that they are required to comply with Regulation M promulgated under the Securities Exchange
Act during such time as it may be engaged in a distribution of the shares. The foregoing may affect the marketability of the common
stock. 

 

     

     

    

 

The
aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of
the common stock less discounts or commissions, if any. The selling stockholders reserve the right to accept and, together with
their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through
agents. We will not receive any of the proceeds from this offering.

 

We
are required to pay all fees and expenses incident to the registration of the shares. We have agreed to indemnify the selling
stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act or otherwise.

 

We
have agreed with the selling stockholders to keep the registration statement of which this prospectus constitutes a part effective
until the earlier of (a) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance
with the registration statement, and (b) the date on which the shares of common stock covered by this prospectus may be sold by
non-affiliates without any volume or manner of sale restrictions or current public information pursuant to Rule 144 of the Securities
Act. 

 

     

     

    

 

Annex
B

 

CORINDUS
VASCULAR ROBOTICS, INC.

 

SELLING
STOCKHOLDER NOTICE AND QUESTIONNAIRE

 

The
undersigned holder of shares of the common stock, par value $0.0001 per share, of Corindus Vascular Robotics, Inc. (the “Company”)
understands that the Company intends to file with the Securities and Exchange Commission a registration statement on Form S-3,
or if Form S-3 is not available, Form S-1 (the “Resale Registration Statement”) for the registration
and the resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the
Registrable Securities in accordance with the terms of the Registration Rights Agreement. All capitalized terms not otherwise
defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement. 

 

In
order to sell or otherwise dispose of any Registrable Securities pursuant to the Resale Registration Statement, a holder of Registrable
Securities generally will be required to be named as a selling stockholder in the related prospectus or a supplement thereto (as
so supplemented, the “Prospectus”), deliver the Prospectus to purchasers of Registrable Securities (including
pursuant to Rule 172 under the Securities Act) and be bound by the provisions of the Registration Rights Agreement (including
certain indemnification provisions, as described below). Holders must complete and deliver this Notice and Questionnaire in order
to be named as selling stockholders in the Prospectus.

 

Certain
legal consequences arise from being named as a selling stockholder in the Resale Registration Statement and the Prospectus. Holders
of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or
not named as a selling stockholder in the Resale Registration Statement and the Prospectus. 

 

NOTICE

 

The
undersigned holder (the “Selling Stockholder”) of Registrable Securities hereby gives notice to the
Company of its intention to sell or otherwise dispose of Registrable Securities owned by it and listed below in Item (3), unless
otherwise specified in Item (3), pursuant to the Resale Registration Statement. The undersigned, by signing and returning this
Notice and Questionnaire, understands and agrees that it will be bound by the terms and conditions of this Notice and Questionnaire
and the Registration Rights Agreement.

 

The
undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate
and complete:

 

QUESTIONNAIRE

 

		1.	Name.

 

		(a)	Full
                                         Legal Name of Selling Stockholder:

 

		 	____________________________

 

		(b)	Full
                                         Legal Name of Registered Holder (if not the same as (a) above) through which Registrable
                                         Securities Listed in Item 3 below are held:

 

		 	____________________________

  

     

     

    

 

		(c)	Full
                                         Legal Name of Natural Control Person (which means a natural person who directly or indirectly
                                         alone or with others has power to vote or dispose of the securities covered by the questionnaire):

 

____________________________

 

		2.	Address
                                         for Notices to Selling Stockholder:

 

	 
	 
	 
	Telephone:_________________________________________________________________________________________________________________________________________________________________     	 
	Fax:_____________________________________________________________________________________________________________________________________________________________________     	 
	Contact Person:_____________________________________________________________________________________________________________________________________________________________     	 
	E-mail address of Contact Person: _______________________________________________________________________________________________________________________________________________     	 
	 

		3.	Beneficial
                                         Ownership of Registrable Securities:

 

		(a)	Type
                                         and Number of Registrable Securities beneficially owned:

 

____________________________

 

____________________________

 

____________________________

 

		(b)	Number
                                         of shares of Common Stock to be registered pursuant to this Notice for resale:

 

____________________________

 

____________________________

 

____________________________

 

		4.	Broker-Dealer
                                         Status:

 

		(a)	Are
                                         you a broker-dealer?

 

Yes
☐        No ☐

 

		(b)	If
                                         “yes” to Section 4(a), did you receive your Registrable Securities as compensation
                                         for investment banking services to the Company?

 

Yes
☐       No ☐

 

		Note:	If
                                         no, the Commission’s staff has indicated that you should be identified as an underwriter
                                         in the Registration Statement.

 

		(c)	Are
                                         you an affiliate of a broker-dealer?

 

Yes
☐      No ☐

 

Note:      If
yes, provide a narrative explanation below:

 

____________________________

 

____________________________

 

     

     

    

 

		(d)	If
                                         you are an affiliate of a broker-dealer, do you certify that you bought the Registrable
                                         Securities in the ordinary course of business, and at the time of the purchase of the
                                         Registrable Securities to be resold, you had no agreements or understandings, directly
                                         or indirectly, with any person to distribute the Registrable Securities?

 

Yes
☐      No ☐

 

		Note:	If
                                         no, the Commission’s staff has indicated that you should be identified as an underwriter
                                         in the Registration Statement.

 

		5.	Beneficial
                                         Ownership of Other Securities of the Company Owned by the Selling Stockholder.

 

Except
as set forth below in this Item 5, the undersigned is not the beneficial or registered owner of any securities of the Company
other than the Registrable Securities listed above in Item 3.

 

Type
and amount of other securities beneficially owned:

 

_________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________

 

_________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________

 

		6.	Relationships
                                         with the Company:

 

Except
as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners
of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship
with the Company (or its predecessors or affiliates) during the past three years.

 

State
any exceptions here:

 

__________________________________________________________________________________________________________________

__________________________________________________________________________________________________________________

__________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________

 

		7.	Plan
                                         of Distribution:

 

The
undersigned has reviewed the form of Plan of Distribution attached as Annex A to the Registration Rights Agreement, and hereby
confirms that, except as set forth below, the information contained therein regarding the undersigned and its plan of distribution
is correct and complete.

 

State
any exceptions here:

 __________________________________________________________________________________________________________________

__________________________________________________________________________________________________________________

 

     

     

    

 

The
undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur
subsequent to the date hereof and prior to the effective date of any applicable Resale Registration Statement. All notices hereunder
and pursuant to the Registration Rights Agreement shall be made in writing, by hand delivery, confirmed or facsimile transmission,
first-class mail or air courier guaranteeing overnight delivery at the address set forth below. In the absence of any such notification,
the Company shall be entitled to continue to rely on the accuracy of the information in this Notice and Questionnaire.

 

By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items (1) through
(7) above and the inclusion of such information in the Resale Registration Statement and the Prospectus. The undersigned understands
that such information will be relied upon by the Company in connection with the preparation or amendment of any such Registration
Statement and the Prospectus.

 

By
signing below, the undersigned acknowledges that it understands its obligation to comply, and agrees that it will comply, with
the provisions of the Exchange Act and the rules and regulations thereunder, particularly Regulation M in connection with any
offering of Registrable Securities pursuant to the Resale Registration Statement. The undersigned also acknowledges that it understands
that the answers to this Questionnaire are furnished for use in connection with Registration Statements filed pursuant to the
Registration Rights Agreement and any amendments or supplements thereto filed with the Commission pursuant to the Securities Act.

 

The
undersigned hereby acknowledges and is advised of the following Interpretation A.65 of the July 1997 SEC Manual of Publicly Available
Telephone Interpretations regarding short selling:

 

“An
Issuer filed a Form S-3 registration statement for a secondary offering of common stock which is not yet effective. One of the
selling stockholders wanted to do a short sale of common stock “against the box” and cover the short sale with registered
shares after the effective date. The issuer was advised that the short sale could not be made before the registration statement
become effective, because the shares underlying the short sale are deemed to be sold at the time such sale is made. There would,
therefore, be a violation of Section 5 if the shares were effectively sold prior to the effective date.”

 

By
returning this Questionnaire, the undersigned will be deemed to be aware of the foregoing interpretation.

 

I
confirm that, to the best of my knowledge and belief, the foregoing statements (including, without limitation the answers to this
Questionnaire) are correct.

 

     

     

    

  

Annex B

 

IN
WITNESS WHEREOF the undersigned, by authority duly given, has caused this Questionnaire to be executed and delivered either in
person or by its duly authorized agent.

 

	Dated:	 	 	Beneficial Owner:	 
	 	 	 

	 	By:	 
	 	 	Name:
	 	 	Title:

 

[Signature Page to Selling Stockholder Notice and Questionnaire]

 

     

     

    

  

Exhibit C-1

 

ACCREDITED INVESTOR QUESTIONNAIRE 

(ALL INFORMATION WILL BE TREATED CONFIDENTIALLY)

 

To:         Corindus Vascular Robotics, Inc.

 

This Investor Questionnaire (this “Questionnaire”)
must be completed by each potential investor in connection with the offer and sale of the shares of the common stock, par value
$0.0001 per share (the “Securities”), of Corindus Vascular Robotics, Inc., a Delaware corporation (the
“Company”). The Securities are being offered and sold by the Company without registration under the Securities
Act of 1933, as amended (the “Act”), and the securities laws of certain states, in reliance on the exemptions
contained in Section 4(2) of the Act and on Regulation D promulgated thereunder and in reliance on similar exemptions under
applicable state laws. The Company must determine that a potential investor meets certain suitability requirements before offering
or selling Securities to such investor. The purpose of this Questionnaire is to assure the Company that each investor will meet
the applicable suitability requirements. The information supplied by you will be used in determining whether you meet such criteria,
and reliance upon the private offering exemptions from registration is based in part on the information herein supplied.

 

This Questionnaire does not constitute
an offer to sell or a solicitation of an offer to buy any security. Your answers will be kept strictly confidential. However, by
signing this Questionnaire, you will be authorizing the Company to provide a completed copy of this Questionnaire to such parties
as the Company deems appropriate in order to ensure that the offer and sale of the Securities will not result in a violation of
the Act or the securities laws of any state and that you otherwise satisfy the suitability standards applicable to purchasers of
the Securities. All potential investors must answer all applicable questions and complete, date and sign this Questionnaire. Please
print or type your responses and attach additional sheets of paper if necessary to complete your answers to any item.

 

		PART A.	BACKGROUND INFORMATION

 

Name of Beneficial Owner of the Securities: __________________________________________________________________________________________

 

	Business Address:	 
	 	(Number and Street)

	 	 	 
	(City)	(State)	(Zip Code)

 

	Telephone Number: (__)	 

 

If a corporation, partnership, limited liability company, trust or other entity:  

 

	Type of entity:	 

 

	State of formation:	 

 

	Approximate Date of formation:	 

 

Were you formed for the purpose of
investing in the securities being offered?        Yes ____ No ____

 

    	 

     

    

 

If an individual:

 

	Residence Address:	 	 	 	 
	 	(Number and Street)	 
	 	 	 	 
	(City)	 	(State)	(Zip Code)
	 	 	 	 
	Telephone Number: (___) _________________________________________________________________________________________________________
	 	 	 	 
	Age:______________	Citizenship:________________	Where registered to vote:___________________________________________

 

Set forth in the space provided below the
state(s), if any, in the United States in which you maintained your residence during the past two years and the dates during which
you resided in each state:

 

Are you a director or executive officer
of the Company?       Yes ____ No ____

 

Social Security or Taxpayer Identification No.: _______________________________________________________________________________________

 

		PART B.	ACCREDITED INVESTOR
                                         QUESTIONNAIRE

 

In order for the Company
to offer and sell the Securities in conformance with state and federal securities laws, the following information must be obtained
regarding your investor status. Please initial each category applicable to you as a Purchaser of Securities of the Company.

 

______ (1)
      A bank as defined in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined
in Section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity;

 

______ (2)
       A broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934;

 

______ (3)
       An insurance company as defined in Section 2(13) of the Securities Act;

 

______ (4)
       An investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section
2(a)(48) of such act;

 

______ (5)
       A Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small
Business Investment Act of 1958;

 

______ (6)       A
plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political
subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000;

 

______ (7)
       An employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, if the investment decision
is made by a plan fiduciary, as defined in Section 3(21) of such act, which is either a bank, savings and loan association, insurance
company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed
plan, with investment decisions made solely by persons that are accredited investors;

 

    	 

     

    

 

______ (8)
       A private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;

 

______ (9)
      An organization described in Section 501(c)(3) of the Internal Revenue Code, a corporation, Massachusetts or similar business
trust, or partnership, not formed for the specific purpose of acquiring the Securities, with total assets in excess of $5,000,000;

 

______ (10)
     A trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Securities, whose
purchase is directed by a sophisticated person who has such knowledge and experience in financial and business matters that such
person is capable of evaluating the merits and risks of investing in the Company;

 

______ (11)
     A natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase
exceeds $1,000,000 (excluding the value of such persons’ primary residence);

 

______ (12)
     A natural person who had an individual income in excess of $200,000 in each of the two most recent years, or joint income with
that person’s spouse in excess of $300,000, in each of those years, and has a reasonable expectation of reaching the same
income level in the current year;

 

______ (13)
     An executive officer or director of the Company;

 

______ (14)
     An entity in which all of the equity owners qualify under any of the above subparagraphs. If the undersigned belongs to this
investor category only, list the equity owners of the undersigned, and the investor category which each such equity owner satisfies.

 

[Remainder
of Page Intentionally Left Blank; Signature Page Follows]

 

    	 

     

    

 

	A.	FOR EXECUTION BY AN INDIVIDUAL:
	 	 

	 	By:	 	 	 
	 	 	 	 	 
	 	Name:	 	 	 	 
	 	 	 	 
	 	Title:	 	 
	 	 	 	 
	 	Date:	 	 
	 	 	 

	B.	FOR EXECUTION BY AN ENTITY:
	 	 

	 	Entity Name:	 	 
	 	 	 
	 	By:	 	 	 
	 	 	 	 	 
	 	Name:	 	 	 	 
	 	 	 	 	 	 
	 	Title:	 	 
	 	 	 

	C.	ADDITIONAL SIGNATURES (if required by partnership, corporation or trust document):
	 	 

 

	 	Entity Name:	 	 
	 	 	 
	 	By:	 	 	 
	 	 	 	 	 
	 	Name:	 	 	 	 
	 	 	 	 	 	 
	 	Title:	 	 
	 	 	 

	 	Entity Name:	 	 
	 	 	 
	 	By:	 	 	 
	 	 	 	 	 
	 	Name:	 	 	 	 
	 	 	 	 	 	 
	 	Title:	 	 
	 	 	 

[Signature Page to Accredited Investor Questionnaire]

 

    	 

 

    

 

Exhibit C-2

 

STOCK CERTIFICATE QUESTIONNAIRE

 

Pursuant to Section 2.2(b)(vi)
of the Agreement, please provide us with the following information:

 

	1.	The exact name that the Securities are to be registered in (this is the name that will appear on
the stock certificate(s)). You may use a nominee name if appropriate: 
	 	 
	 	 
	 	 

 

	2.	The relationship between the Purchaser of the Securities and the Registered Holder listed in response
to Item 1 above: 
	 	 
	 	 
	 	 

 

	3.	The mailing address, email address, telephone number, and facsimile number of the Registered Holder
listed in response to Item 1 above: 
	 	 
	 	 
	 	 
	 	 
	 	 

 

	4.	The Tax Identification Number (or, if an individual, the Social Security Number) of the Registered Holder listed in response
to Item 1 above: 
	 	 
	 	 

 

    

    

    

 

Exhibit D

 

Form of Opinion of Company Counsel

 

1.          The
Company is a corporation duly incorporated, validly existing and in good standing under the laws of Delaware. The Company has all
requisite corporate power and authority to (a) enter into and perform its obligations under the Transaction Documents and (b) own
and operate its properties and assets and to carry on its business as now conducted and as proposed to be conducted (as described
in the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2015) (the “Annual Report”).
The Company is duly qualified to transact business and is in good standing in the Commonwealth of Massachusetts.

 

2.          Each
of the Transaction Documents constitutes the valid and binding agreement of the Company, enforceable against the Company in accordance
with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, fraudulent conveyance, reorganization,
arrangement, moratorium or other similar laws affecting creditors’ rights generally, and subject to general equity principles
and to limitations on availability of equitable relief, including specific performance.

 

3.          The
execution, delivery and performance of the Transaction Documents by the Company, the compliance with the terms and provisions thereof
by the Company and the issuance and sale of the Securities by the Company will not (a) violate the provisions of the Company’s
Certificate of Incorporation or Bylaws, (b) violate any law, rule or regulation of the United States of America, the Commonwealth
of Massachusetts or the State of Delaware that in our experience is normally applicable to transactions of the type contemplated
by the Transaction Documents or (c) violate any agreement to which the Company is a party or bound (this opinion being limited
(i) to those agreements identified on Exhibit A attached hereto (the “Material Contracts”) and (ii) in
that we express no opinion with respect to any violation or default (x) arising under or based upon any cross-default provision
insofar as it relates to a violation or default under an agreement not identified on Exhibit A attached hereto, (y) arising
as a result of any violation or default under any agreement or covenant by failure to comply with any financial or numerical requirement
requiring computation or (z) under any provisions therein relating to the occurrence of a “material adverse event”
or words of similar import).

 

4.          No
consent, approval, authorization or order of, or filing, declaration or registration with, any federal, Delaware or Massachusetts
governmental agency or body or any court is required in connection with the execution, delivery or performance of the Transaction
Documents by the Company, or in connection with the issuance or sale of the Securities by the Company to the Purchasers, except
(i) the filing with the Securities and Exchange Commission of one or more Registration Statements in accordance with the requirements
of the Registration Rights Agreement, (ii) filings required by applicable state securities laws, (iii) the filing of a Notice of
Sale of Securities on Form D with the Securities and Exchange Commission under Regulation D of the Securities Act of 1933, as amended,
(iv) the filing of any requisite notices and/or application(s) to the NYSE MKT for the issuance and sale of the Securities for
trading or quotation, as the case may be, thereon in the time and manner required thereby, and (v) those that have been made or
obtained prior to the date hereof.

 

5.          It
is not necessary in connection with the offer and sale of the Securities to the Purchasers under the Purchase Agreement to register
the Securities under the Securities Act of 1933, as amended, assuming the accuracy of the representations and warranties of the
Purchasers in the Purchase Agreement.

 

6.          To
our actual knowledge, there is no litigation or any governmental proceeding involving the Company, pending or threatened, that
challenges the validity or enforceability of the Purchase Agreement or the Registration Rights Agreement, or seeks to enjoin the
performance of the Purchase Agreement or the Registration Rights Agreement by the Company.

 

    	 

     

    

 

7.          The
Company is not required to register as an “investment company,” as such term is defined in the Investment Company Act
of 1940, as amended.

 

8.          The
Securities have been duly authorized and, upon issuance, delivery and payment therefor as described in the Purchase Agreement,
will be validly issued, fully paid and nonassessable. The issuance and sale of the Securities are not subject to any preemptive
or similar rights under the Company’s Certificate of Incorporation or Bylaws or under any Material Contract other than as
set forth on Schedule I hereto.

 

9.          The
execution, delivery and performance of the Transaction Documents have been duly authorized by all necessary corporate action of
the Company, and the Transaction Documents have been duly executed and delivered by the Company.

 

    	 

 

    

 

Exhibit E

 

CORINDUS VASCULAR ROBOTICS, INC.

 

[●], 2017

 

Manhattan Transfer Registrar Company

57 Eastwood Road 

Miller Place, New York 11764

Attn: [●]

 

Ladies and Gentlemen:

 

Reference is made to that certain
Securities Purchase Agreement, dated as of [●], 2017 (the ”Agreement”), by and among Corindus
Vascular Robotics, Inc., a Delaware corporation (the ”Company”), and the purchasers named therein
(collectively, and including permitted transferees, the “Holders”), pursuant to which the Company is
issuing to the Holders shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”).

 

By this letter, you are irrevocably
authorized and directed to issue an aggregate of [●] shares of the Company’s Common Stock (the “Shares”).
The Shares should be issued as [book restricted shares] in the names and denominations specified on Schedule I hereto. The
Shares have not been registered and are, therefore, “restricted shares.” Accordingly, the Common Shares should bear
the following restricted legend:

 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY
NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION
OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

 

The Shares may be issued to any Holder
in certificate form (each, a “Certificate” and collectively, the “Certificates”)
upon request. Any Certificate issued should contain the aforementioned legend.

 

This letter shall also serve as our
irrevocable authorization and direction to you (provided that you are the transfer agent of the Company at such time and the conditions
set forth in this letter are satisfied), subject to any stop transfer instructions that we may issue to you from time to time,
if any, to issue shares of Common Stock upon transfer or resale of the Shares.

 

You acknowledge and agree that so
long as you have received written confirmation from the Company’s legal counsel that a registration statement covering resales
of the Shares has been declared effective by the Securities and Exchange Commission (the “Commission”)
under the Securities Act of 1933, as amended (the “Securities Act”), and a copy of such registration
statement, then, unless otherwise required by law, you shall use your commercially reasonable efforts to issue the certificates
representing the Shares registered in the names of such Holders or transferees, as the case may be, within three (3) Business Days
of your receipt of a notice of transfer of Shares, and such certificates shall not bear any legend restricting transfer of the
Shares thereby and should not be subject to any stop-transfer restriction.

 

    

     

    

 

[●], 2017

Page 2

 

A form of written confirmation from
the Company’s outside legal counsel that a registration statement covering resales of the Shares has been declared effective
by the Commission under the Securities Act (which confirmation shall be delivered to you upon effectiveness of the registration
statement) is attached hereto as Annex A.

 

Please be advised that the Holders
are relying upon this letter as an inducement to enter into the Agreement and, accordingly, each Holder is a third party beneficiary
to these instructions.

 

Please execute this letter in the space indicated to acknowledge
your agreement to act in accordance with these instructions.

 

[Remainder of Page Intentionally Left Blank; Signature
Page Follows]

 

    

     

    

 

	 	Very truly yours,
	 	 	 
	 	CORINDUS VASCULAR ROBOTICS, INC.
	 	 
	 	By:	
	 	Name: Mark J. Toland
	 	Title: Chief Executive Officer and President

  

Acknowledged and Agreed:

 

Manhattan Transfer Registrar Company

 

	By:	 	 	 
	Name:	 
	Title:	 	 
	 	 	 	 

Date: __________________________, 2017

 

[Signature Page to Authorization Letter to Transfer Agent]

 

    

     

    

 

Schedule I

 

Holders

 

	Holders	Address	EIN	Common

Shares
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

 

    

     

    

 

Annex A

 

FORM OF NOTICE OF EFFECTIVENESS OF REGISTRATION
STATEMENT

 

Manhattan Transfer Registrar Company

57 Eastwood Road 

Miller Place, New York 11764

Attn: _________________

 

Re: Corindus Vascular Robotics, Inc.

 

Ladies and Gentlemen:

 

Corindus Vascular Robotics, Inc.,
a Delaware corporation (the “Company”), has entered into a Securities Purchase Agreement, dated as of
[●], 2017, with the buyers named therein (collectively, the ”Purchasers”) pursuant to which
the Company issued to the Purchasers shares of the Company’s common stock, $0.0001 par value per share (the “Common
Stock”). Pursuant to that certain Registration Rights Agreement of even date, the Company agreed to register the
resale of the Common Stocks (the ”Registrable Securities”), under the Securities Act of 1933, as
amended (the “Securities Act”). In connection with the Company’s obligations under the Registration
Rights Agreement, on [___], 2017, the Company filed a Registration Statement on Form S-3 (File No. 333-                    )
(the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”)
relating to the Registrable Securities which names each of the Purchasers as a selling stockholder thereunder and set forth as
Exhibit A hereto.

 

In connection with the foregoing,
we advise you that a member of the Commission’s staff has advised us by telephone that the Commission has entered an order
declaring the Registration Statement effective under the Securities Act at ____ [a.m.][p.m.] on [___], 2017, and we have no knowledge,
after telephonic inquiry of a member of the staff, that any stop order suspending its effectiveness has been issued or that any
proceedings for that purpose are pending before, or threatened by, the Commission and the Registrable Securities are available
for resale under the Securities Act pursuant to the Registration Statement. Based upon the foregoing, we are of the opinion that
as of the date of this opinion, the Registrable Securities have been duly authorized and, when issued by you, will be validly issued,
fully paid and non-assessable, and are registered for resale under the Securities Act under the effective Registration Statement
and may be issued without a restrictive legend.

 

This letter shall serve as our standing
notice to you that the Common Stock may be freely transferred by the Purchasers pursuant to the Registration Statement. You need
not require further letters from us to effect any future legend-free issuance or reissuance of shares of Common Stock to the Purchasers
or the transferees of the Purchasers, as the case may be, as contemplated by the Company’s Irrevocable Transfer Agent Instructions
dated [●], 2017, provided at the time of such reissuance, the Company has not otherwise notified you that the Registration
Statement is unavailable for the resale of the Registrable Securities. This letter shall serve as our standing instructions with
regard to this matter.

 

[Remainder of Page Intentionally Left Blank;
Signature Page Follows]

 

    

     

    

 

	 	Very truly yours,
	 	 	 
	 	CORINDUS VASCULAR ROBOTICS, INC.
	 	 
	 	By:	
	 	Name: Mark J. Toland
	 	Title: Chief Executive Officer and President

 

[Signature Page to Notice of Effectiveness of Registration Statement]

 

    

     

    

 

Exhibit A

 

Registration Statement

 

    

     

    

 

Exhibit F

 

corindus vascular
robotics, Inc.

 

Secretary’s Certificate

 

[●], 2017

 

The undersigned
hereby certifies that he is the duly elected, qualified and acting Secretary of Corindus Vascular Robotics, Inc., a Delaware
corporation (the “Company”), and that as such he is authorized to execute and deliver this
certificate in the name and on behalf of the Company, pursuant to Section 2.2(a)(v) of the Securities Purchase Agreement,
dated as of [●], 2017, by and among the Company and the purchasers party thereto (the “Securities Purchase
Agreement”), and further certifies in his official capacity, in the name and on behalf of the Company, the
items set forth below. Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the
Securities Purchase Agreement.

 

		1.	Attached hereto as Exhibit A is a true, correct and complete copy of the resolutions duly
adopted by the Board of Directors of the Company and any duly authorized committee thereof by unanimous written consent on [●],
2017 approving the transactions contemplated by the Securities Purchase Agreement and the other Transaction Documents and the issuance
of the Securities. Such resolutions have not in any way been amended, modified, revoked or rescinded, have been in full force and
effect since their adoption and are now in full force and effect and are the only resolutions adopted by the Board of Directors
of the Company or any duly authorized committee thereof relating to the transactions contemplated by the Transaction Documents.

 

		2.	Attached hereto as Exhibit B-1 is a true, correct and complete copy of the Certificate of
Incorporation of the Company, together with any and all amendments thereto, and no action has been taken to further amend, modify
or repeal such Certificate of Incorporation, the same being in full force and effect as of the date hereof. Attached hereto as
Exhibit B-2 is a true, correct and complete copy of the Bylaws of the Company, together with any and all amendments thereto,
and no action has been taken to further amend, modify or repeal such Bylaws, the same being in full force and effect as of the
date hereof.

 

		3.	Each person listed below has been duly elected or appointed to the position(s) indicated opposite
his name and is duly authorized to sign the Securities Purchase Agreement and each of the Transaction Documents on behalf of the
Company, and the signature appearing opposite such person’s name below is such person’s genuine signature.

 

	 	Name	Title	Signature
	 	Mark J. Toland	Chief Executive Officer and President	 
	 	David W. Long	Chief Financial Officer and Senior Vice President, Secretary and Treasurer 	 

 

 

[Remainder of Page Intentionally Left Blank; Signature
Page Follows]

 

    

     

    

 

IN WITNESS WHEREOF, the undersigned
have executed this certificate as of the date first set forth above.

 

	 	 
	 	David W. Long
	 	Secretary

 

I, Mark J. Toland, Chief Executive
Officer and President, hereby certify that David W. Long is the duly elected, qualified and acting Secretary of the Company and
that the signature set forth above is his true signature.

	 	 
	 	Mark J. Toland
	 	Chief Executive Officer and President

 

[Signature Page
to Secretary’s Certificate]

 

    

     

    

	

 

Exhibit A

 

Board Resolutions

 

    

     

    

 

Exhibit B-1

 

Certificate of Incorporation

 

    

     

    

 

Exhibit B-2

 

Bylaws

 

    

 

    

 

Exhibit G

 

Corindus
vascular robotics, Inc.

 

Compliance
Certificate

 

[●],
2017

 

The
undersigned, the Chief Executive Officer and President of Corindus Vascular Robotics, Inc., a Delaware corporation (the “Company”),
pursuant to Section 2.2(a)(vi) of the Securities Purchase Agreement, dated as of [●], 2017, by and among the Company and
Purchasers (as defined therein) (the “Securities Purchase Agreement”), hereby represents, warrants
and certifies as follows (capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Securities
Purchase Agreement):

 

		1.	The
                                         representations and warranties made by the Company in Section 3.1 of the Securities Purchase
                                         Agreement are true and correct in all material respects (except for those representations
                                         and warranties which are qualified as to materiality, in which case such representations
                                         and warranties are true and correct in all respects) as of the date when made and as
                                         of the date hereof, as though made on and as of such date, except for such representations
                                         and warranties that speak as of a different specified date.

 

		2.	The
                                         Company has performed, satisfied and complied in all material respects with all covenants,
                                         agreements and conditions required by the Transaction Documents to be performed, satisfied
                                         or complied with by it at or prior to the date hereof.

 

		3.	As
                                         of the date hereof, (a) neither the Company nor any of its Subsidiaries shall have taken
                                         any steps to seek protection pursuant to any law or statute relating to bankruptcy, insolvency,
                                         reorganization, receivership, liquidation or winding up; (b) neither the Company nor
                                         any of its Subsidiaries shall have received any notice from their respective creditors
                                         that such creditors intend to (I) initiate involuntary bankruptcy proceedings or (II)
                                         accelerate any amounts owing from the Company or any of its Subsidiaries to such creditor;
                                         (c) neither the Company nor any of its Subsidiaries, individually and on a consolidated
                                         basis, shall be insolvent; and (d) except as set forth in Section 3.1(k) of the Disclosure
                                         Schedule, neither the Company nor any of its Subsidiaries shall have engaged in any business
                                         or in any transaction, and shall not be about to engage in any business or in any transaction,
                                         for which the Company’s or such Subsidiary’s remaining assets constitute
                                         unreasonably small capital.

 

[Remainder
of Page Intentionally Left Blank; Signature Page Follows]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the undersigned has executed this certificate as of the date first set forth above.

 

	 	 	 
	 	Mark J. Toland
	 	Chief Executive Officer and President

 

[Signature Page to Compliance Certificate]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]